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Studies using animal models have found considerable evidence of neurological damage 
resulting from exposure to 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Yet, studies 
comparing the cognitive performance of human recreational ecstasy users to ecstasy naïve 
controls have produced inconsistent results.  The present study is a meta-analysis of the 
published empirical literature on the cognitive sequelae of human recreational ecstasy use. The 
pooled effect size estimate for combined cognitive domains was statistically significant and 
moderate in size.  Small to large, statistically significant aggregate effect sizes resulted for eight 
of the nine cognitive ability domains included in the analysis.  Moderator analyses suggested that 
frequent ecstasy use is associated with greater cognitive impairment, cognitive impairment can 
occur after relatively low amounts of total lifetime cumulative use, and recovery of functioning 
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Acute administration of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) 
stimulates the release and inhibits the reuptake of serotonin (5-hydroxytryptamine, 5-HT). In 
addition to being a serotonin agonist, MDMA more subtly increases the availability of 
norepinephrine and dopamine. It is chemically similar to endogenous catecholamines and 
neurotransmitters, but it is a synthetic mescaline analogue (Buchanan & Brown, 1988).  
Recreational users report acute effects of euphoria, feelings of intimacy, self-confidence, and 
openness to new ideas (Morgan, 2000). 
In the past, some psychotherapists have administered MDMA to their patients to increase 
empathy and self-esteem during therapy sessions (Chiarello & Cole, 1987; Grinspoon & Bakalar, 
1986; Shulgin, 1986).  The U.S. Drug Enforcement Agency designated MDMA as a Schedule I 
controlled substance in 1986, thereby ending the legal use of MDMA by psychotherapists 
(Steele, McCann, & Ricaurte, 1994).  MDMA has been more recently considered for use in 
psychotherapy (Greer & Tolbert, 1998) and within the past few years, the U.S. Food and Drug 
Administration (FDA) has approved clinical trials of the use of MDMA as an adjunct to 
posttraumatic stress disorder treatment (Imperio, 2001; Mithoefer, 2003).   
Despite its illegal status, ecstasy continues to be a popular recreational drug.  In 2003, 
4.6% of Americans responding to the National Survey on Drug Use and Health had used ecstasy 
at least once in their lifetimes (Office of Applied Studies, Substance Abuse and Mental Health 
Services Administration, 2005).  Ecstasy use is increasingly becoming popular in China (Yip & 
Lee, 2005) and has been acknowledged as a public health threat worldwide (Kish, 2002; 
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Montoya et al., 2002).  However, the degree to which ecstasy truly poses a public health threat 
has been controversial (Green, 2004). 
Reviews of animal studies note that repeated administration of MDMA has been found to 
result in lasting decreases of 5-HT and 5-HIAA (serotonin metabolite) concentrations in areas of 
the brain that are typically associated with attention, memory, and executive functioning in 
humans (Curran, 2000; Montoya, Sorrentino, Lukas, & Price, 2002; Morgan, 2000).  
Neurological effects of MDMA have been found in non-human primates for up to seven years 
post drug administration (Hatzidimitriou, McCann, & Ricaurte, 1999).  On the other hand, 
animal studies have also found evidence of some neuronal recovery one year post exposure.  
Regeneration has been found to differ from the original innervation pattern, however, with the 
dorsal neocortex remaining denervated and the amygdala and the hypothalamus evidencing 
recovery or hyperinnervation (Fischer, Hatzidimitriou, Wlos, Katz, Ricaurte, 1995; 
Hatzidimitriou et al., 1999; Steele et al., 1994).     
There appears to be a dose-response relationship between the amount of ingested MDMA 
and the amount of serotonergic neuronal damage, but it is unclear how much MDMA is required 
to produce long term neurological changes.  Dose-dependent reductions in 5-HT, 5-HIAA, 
tryptophan hydroxylase, and 5-HT uptake sites have been found in a variety of animal species 
(Parrott, 2002).  However, repeated lower doses of MDMA have not been found to produce signs 
of neurodegeneration in many animal studies (Vollenweider, et al, 1999).  One review of animal 
studies concluded that long-term neurological MDMA-related damage requires either a large 
single dose or several more moderate doses, taken twice daily for four consecutive days 
(Morgan, 2000).   Not only are the doses required to generate lasting neurological damage in 
animals contested in the literature, there is also debate about the degree to which the possible 
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dose-response relationship found in animals can be generalized to humans (Lyles & Cadet, 2003; 
Morgan, 2000; Parrott, 2002). 
Furthermore, there is controversy about whether long term serotonergic damage results 
from human recreational ecstasy use at all, given the manner in which it is typically used by 
humans (Green, 2004).  Although serotonergic neuronal damage has been repeatedly found in 
animals, the doses are high and the findings may not directly translate to humans (Parrott, 2002).  
In many of the animal studies, subjects were injected with large doses repeatedly over a period of 
days (Boot, McGregror, & Hall, 2000).  MDMA is two to three times more toxic when it is 
injected than when it is orally administered to animals (Ricaurte, DeLanney, Irwin, & Langston, 
1988).  Human recreational ecstasy users do not typically inject the drug.  Usually, recreational 
users orally consume ecstasy and many consumers use it once per week or less because tolerance 
for the pleasurable effects develops quickly (Morgan, 2000).  Some consumers, however, use 
large doses to achieve the desired response if they take ecstasy more frequently (Solowij, Hall, & 
Lee, 1992).  Although it is not clear that human recreational ecstasy users typically consume 
enough ecstasy to produce neuronal damage that would lead to measurable differences in long 
term cognitive performance (Green, 2004), there exists variability in human recreational use 
patterns and, consequently, there may exist variability in the associated cognitive sequelae.  
Some studies have found support for a relationship between cognitive performance and amount 
of exposure to ecstasy in humans, generally finding differences between participants variously 
divided into light and heavy use groups (Morgan, 1999; Gouzoulis-Mayfrank et al., 2000; 
Parrott, Buchanan, et al., 2002).  A longitudinal study found a relationship between continued 
ecstasy use and cognitive performance, suggesting that the period of time that a person has used 
ecstasy can impact degree of deficit in functioning (Zakzanis & Young, 2001) and one study 
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identified total lifetime cumulative ecstasy use as the strongest predictor of impaired cognitive 
performance (Bhattachary & Powell, 2001).         
In addition to possible differences between the quantities of MDMA administered to 
study animals and the amount of exposure that is typical for human recreational ecstasy users, 
there are other reasons to believe that the recreational use of ecstasy by humans would be less 
likely to result in neurological damage.  For example, animal studies have demonstrated that use 
of MDMA increases oxidative stress while marijuana use decreases it.  Oxidative stress is 
thought to be a major contributor to the serotonergic neurotoxicity associated with the use of 
MDMA.  It has, therefore, been predicted that concomitant marijuana use might reduce risk of 
MDMA-related neurological damage.  Many human ecstasy users also simultaneously use 
marijuana and may, therefore, be less likely to experience oxidative stress (Parrott, Gouzoulis-
Mayfrank, & Rodgers, 2004).    
There are, however, some reasons to believe that the recreational use of ecstasy by 
humans would be more likely to result in neurological damage.  For example, recreational users 
often take ecstasy in nightclubs and parties where the ambient temperature is high.  At the same 
time, users often do not drink enough water, increasing their risk of hyperthermia.  Hyperthermia 
has been found to intensify MDMA-related neurological damage in rats (Boot et al., 2000).  
Studies using animal models (Lyles & Cadet, 2003) have found considerable evidence for 
neurological damage resulting from exposure to MDMA.  Animal studies strongly suggest that 
MDMA use at some dose will result in damage to serotonergic neurons (Kish, 2002).  Although 
the methods of studying neurological damage in humans are constrained by ethical 
considerations, some researchers have found evidence of ecstasy-related damage in human 
participants.  Neuroimaging of human participants has found that recreational ecstasy users have 
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fewer serotonin transporter sites than do non-users and the amount of difference was found to be 
related to the degree of exposure to ecstasy (McCann, Szabo, Scheffel, Dannals, & Ricaurte, 
1998).  Findings of human studies, however, have not been as definitive as they have been in 
animal studies (Green, 2004).  Some researchers studying human participants have found lower 
5-HIAAA levels measured in the cerebrospinal fluid (Ricaurte, Finnegan, Irwin, & Langston, 
1990; McCann, Ridenour, Shaham, & Ricaurte, 1994) while others have not (Peroutka, Pascoe, 
& Faull, 1987).  Methodological problems associated with studies using human participants 
make it difficult to confirm that ecstasy use results in a chronic serotonin deficiency syndrome.  
In particular, many of the studies in humans rely on markers of serotonergic neuronal integrity 
that can be up-regulated or down-regulated independent of the number of intact neurons.  In 
other words, the markers may not be definitive measures of neurological damage (Kish, 2002).  
Furthermore, adaptive changes may be made in response to damage in a brain area thereby 
reducing the long term results of ecstasy use on cognitive functioning (Robbins, 2005).  
Numerous studies have been conducted measuring the differences in the cognitive 
performance between human recreational ecstasy consumers and ecstasy naïve controls.  Studies 
have generally focused on measures of attention, verbal and nonverbal memory, general 
executive functioning, fluency, learning, and reaction time.  These areas have been the major 
areas of focus in the literature because of the relationship between these domains and 
serotonergic pathways thought to be damaged by exposure to MDMA (Back-Madruga, Boone, & 
Chang, 2003; Buhot; 1997; Curran, 2000; Montoya et al., 2002; Morgan, 2000; Parrott, 2002; 
Reneman, Booij, Majoie, van den Brink, & den Heeten, 2001; Verdejo-Garcia et al., 2004; 
Verkes et al., 2001).   Neuropsychological studies of functional deficits related to ecstasy use 
have produced inconsistent results.  Some studies have found no differences in performance on 
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cognitive measures.  Other studies have found deficits in specific cognitive areas related to 
serotonergic dysfunction, but not other areas and there are inconsistencies in the literature in the 
pattern of specific cognitive deficits (Back-Madruga et al., 2003; Parrott, 2001; Verdejo-Garcia 
et al., 2004).  Finally, deficits in cognitive performance may be related to reversible ecstasy 
withdrawal symptoms.  Researchers have identified a period of ecstasy withdrawal during which 
recreational ecstasy users experience depression, reduced ability to concentrate, irritability, and 
difficulty sleeping (Curran, 2000; Parrott, 2002).   Some recovery of cognitive functioning has 
been found to be related to time since the person last used ecstasy (Bhattachary & Powell, 2001; 
Morgan, 1999; Thomasius et al., 2003) and recovery of cognitive functioning is frequently found 
following extended abstinence from many types of abused substances (Verdejo-Garcia et al., 
2004).  Inconsistencies in the literature on the relationship between cognitive performance and 
ecstasy use might be partially explained by the minimum period of abstinence from ecstasy 
required before cognitive testing. 
It is difficult, due to legal and ethical concerns, to conduct controlled studies of the 
cognitive effects of repeated ecstasy use.  Therefore, most researchers have studied participants 
who have elected to recreationally use ecstasy in the natural environment.  Most recreational 
ecstasy users do not exclusively use ecstasy (Morgan, 1999; Parrott et al., 2000).  Consequently, 
researchers have had difficulty disentangling the residual cognitive consequences of ecstasy use 
from the consequences of polydrug use.  Some researchers have even found that cognitive 
deficits in ecstasy users were explained by marijuana use, rather than ecstasy use (Dafters, 
Hoshi, & Talbot, 2004).   In an attempt to control for the confound, many researchers have 
included polysubstance users in the control group, sometimes comparing polysubstance using 
ecstasy consumers to polysubstance users who have not previously used ecstasy and participants 
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who do not use drugs at all.  Differences in the drug use other than ecstasy between the ecstasy 
use groups and the ecstasy naïve control groups may partially explain the inconsistencies in the 
findings of studies of the long term cognitive sequelae of human ecstasy use (Parrott, 2002).   
Given the popularity of ecstasy, the movement to gain FDA approval to use MDMA in 
psychotherapy (Green, 2004), and the uncertainty regarding the effects of use on cognitive 
functioning, there is a need to empirically digest the extant studies on the relationship between 
recreational ecstasy use and cognitive performance.  Numerous review articles have summarized 
the research on the cognitive sequelae of ecstasy use (Back-Madruga et al., 2003; Curran, 2000; 
Montoya et al., 2002; Morgan, 2000; Parrott, 2000; Parrott, 2002; Parrott, et al., 2004), but the 
authors of narrative reviews might intentionally or unintentionally select and interpret 
combinations of studies in ways that support their own theoretical positions.  The process of 
meta-analysis helps to guard against influence of the author’s bias by demanding that the author 
find all studies testing the hypothesis.  Meta-analysis also requires that the author focus on the 
results of the studies, as opposed to the discussion sections of the papers.  Discussion sections 
often include conclusions that are only weakly implied by the results (Rosenthal & DiMatteo, 
2001).  The present study conducted a meta-analysis of the published empirical literature on the 
cognitive sequelae of recreational ecstasy use.  A goal of the present meta-analysis was to 
evaluate the overall relationship between recreational ecstasy use and cognitive performance in 
domains related to serotonergic dysfunction.  A second goal was to investigate the possible 
differential relationship of ecstasy use to specific cognitive domains.  A third goal was to explore 
possible sources of the inconsistencies in findings between primary studies.    
A preliminary meta-analysis of the literature was completed in 2002 (Verbaten, 2003).   
A total of 14 primary studies were included in the analyses and one outcome measure was 
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selected from each study for each of four cognitive domains (short term memory, long term 
memory, attention measured as percentage correct, attention measured as reaction time).   It was 
concluded that the literature was limited and that many more studies were necessary to 
investigate the possible relationship between cognitive performance and recreational ecstasy use.    
Some recommend that systematic reviews be considered for an update every two years 
(The Cochrane Collaboration, 2005).  Others contend that the decision to update a meta-analysis 
should be based on the number of suitable new primary studies that have been published since 
the previous meta-analysis, as different literatures progress at different rates (Barrowman, Fang, 
Sampson, & Moher, 2003).  The literature focusing on MDMA has increased at an exponential 
rate in recent years.  Publication climbed from approximately 30 studies related to MDMA being 
published per year in the 1990s to more than 100 studies being published per year in the 2000s 
(Green, 2004).   Not all of the studies related to MDMA that have recently flooded the literature 
are studies of the non-acute cognitive sequelae associated with recreational ecstasy use.  
However, a substantial number of studies investigating the cognitive consequences of human 
ecstasy use have been published since Verbaten’s (2003) study was completed in 2002.   
The present meta-analysis replicated, updated, and extended the previously conducted 
meta-analysis.  The present meta-analysis updated the former analysis by including studies that 
were not published at the time of the previous meta-analysis.  A total of 36 primary studies were 
included in the present analysis, more than doubling the study-level sample size of the previously 
conducted meta-analysis.  Inclusion of additional studies increases the confidence that the pooled 
effect size estimates approximate the population parameters (Rosenthal, 1984).  The expanded 
literature also permitted additional sub-analyses of cognitive domains related to serotonergic 
dysfunction that were not included in the previous meta-analysis. Verbaten (2003) limited the 
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analysis to measures of immediate and delayed verbal recall, reaction time, and % correct as a 
measure of attention.  In addition to including measures of immediate and delayed verbal 
memory and reaction time, the present meta-analysis expands to measures of immediate and 
delayed nonverbal memory, executive functioning, fluency, learning, and extensive measures of 
attention.  Many of the primary studies included in Verbaten’s (2003) analysis used multiple 
measures of cognitive functioning.  Yet, Verbaten (2003) limited inclusion to one to four 
cognitive outcome measures per study.  Consequently, a large amount of data from the primary 
studies was excluded and there was an increased chance of bias in the pooled estimates.  The 
present meta-analysis used a method of effect size aggregation that includes all relevant 
cognitive measures from primary studies while guarding against sample size inflation.  Verbaten 
(2003) tested total cumulative ecstasy consumption as a potential moderating variable.  No 
relationship was found between cumulative ecstasy consumption and effect size.  Verbaten 
(2003) concluded that the results suggested an absence of a dose-response relationship between 
cognitive performance and ecstasy use.  The present meta-analysis does not limit investigation of 
moderating potential to total lifetime cumulative use.  Multiple operational definitions of amount 
of exposure to ecstasy were investigated.   Additional moderators were also examined. 
The present meta-analysis tested the following hypotheses. 
1) Ecstasy use is negatively related to quality of cognitive performance, particularly 
as measured by assessments of attention, immediate verbal memory, delayed verbal memory, 
immediate nonverbal memory, delayed nonverbal memory, executive functioning, fluency, 
learning, and reaction time.  
2) The relationship between ecstasy use and cognitive performance is moderated by 
the amount of ecstasy used. If a dose-response relationship exists, it would be expected that 
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larger measurable differences in cognitive performance would occur in those human recreational 
users with greater exposure to ecstasy than would be found in consumers with less exposure. 
3) The relationship between ecstasy use and cognitive performance is moderated by 
the amount of time that has passed since ecstasy was consumed.   It is hypothesized that duration 
of abstinence will be related to fewer differences between the ecstasy use group and the ecstasy 
naïve control group. 
4) The effect size representing the strength of the relationship between ecstasy use 
and cognitive performance will be sensitive to the patterns of drug use, other than ecstasy, 
engaged in by the ecstasy naïve control groups in the primary studies.  
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METHOD 
Search strategy and sample of studies 
 Relevant studies were identified by database searches of PsycINFO, PsycArticles, 
PubMed, and Medline using Boolean combinations of the key words ecstasy, MDMA, and 3-4 
methylene-dioxymethamphetamine with memory, attention, cognitive, cognition, and executive.  
Additionally, the reference lists of included articles and review articles were searched for studies 
that might be added.  The search for relevant studies terminated in June of 2005.  Full text of 
articles that met criteria for selection for further review were obtained.  If there was not enough 
information in the title and abstract to determine if the article met criteria, the full text was 
retrieved.  Criteria for selection for further review were: 
1. study was published in a peer reviewed journal, 
2. study investigated MDMA or ecstasy use, 
3. study was published in English, 
4. subjects were human, 
5. abstract or title suggested that a cognitive measure of participants was likely included in 
the study, 
6. and abstract or title suggested that the study was not limited to the relationship between 
cognitive functioning and acute use.  
 Included studies were limited to those published in a peer reviewed journal for two 
reasons.   First, authors conducting reviews sometimes accidentally or intentionally eliminate 
primary studies that do not support their position (Rosenthal & DiMatteo, 2001).  Limiting 
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included studies to those that can be obtained with relative ease by other meta-analysts increases 
the replicability of the present meta-analysis (personal communication, Donald Penzien, April 
20, 2005).  Increased replicability may lead to increased confidence in the conclusions derived 
from the analysis because readers can be more sure of how studies were excluded.  Second, 
components of methodological quality are tested as potential moderating variables in the present 
analysis.  However, effect sizes from primary studies were not weighted by a global 
methodological quality score.  Decisions on how to weight the primary studies are discussed 
latter in this paper.  While far from perfect, peer review provides some degree of methodological 
quality assurance.  
 The full text of 74 original empirical studies were obtained and reviewed for possible 
inclusion in the meta-analysis.  Criteria for inclusion in the meta-analysis were: 
1. study used a control group that did not contain participants with a history of ecstasy use, 
2. study used behavioral measures of cognitive functioning (i.e., not limited to self-report), 
3. reported results were not limited to multivariate analyses, 
4. manuscript included enough information to compute effect size, 
5. cognitive tests measured memory, attention, and/or executive functioning, 
6. cognitive tests were not limited to measures confounded by affective content, 
7. and participant ecstasy use was prohibited on the day that cognitive testing was 
conducted.  
 A total of 36 manuscripts were retained for the meta-analysis.  One study (von Geusau, et 
al., 2004) reported the results from men and from women separately.  It is recommended that, if 
data are collected from independent groups within the same study, the outcome measures from 
each group can be treated as independent effect sizes from different studies (Hunter, Schmidt, & 
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Jackson, 1982).  As data in the male group was not repeated in data from the female group, the 
results were treated as independent.  Another manuscript (Morgan, 1998) reported the results of 
two separate studies using independent samples.  The results of the two studies were treated as 
independent.  However, results from the sample from one of the two studies were reported in a 
latter manuscript (Morgan, 1999).  Results from the same sample reported in two separate 
manuscripts (Morgan, 1998; 1999) were combined as one study to prevent error associated with 
dependent effect sizes.  Care was taken to investigate the possibility that studies from the same 
laboratory that were published close in time used the same samples.  Demographics and ecstasy 
use patterns were compared between samples to assess for similarity.  Other than Morgan (1998; 
1999), no studies that met criteria for inclusion in the meta-analysis could be determined to have 
used the same participants.  However, the possibility that some of the same participants were 
used in multiple studies can not be ruled out.  The total number of samples treated as 
independent was 37. 
Data from a total of 786 ecstasy consumers and 886 ecstasy naïve controls was included 
in the analysis. See Table 1 for the sample size for each group from each primary study.  
Participants were recruited from the United Kingdom (17 samples), the United States (5 
samples), the Netherlands (6 samples), Germany (4 samples), Canada (2 samples), Australia (2 
samples), and China (1 samples).   
Participants were required to abstain from using ecstasy for a minimum of 1 to 365 days 
before completing cognitive measures.  See Table 2 for the minimum number of days of required 
abstinence by study.  Average cumulative lifetime ecstasy consumption spanned from 10 to 1106 
tablets.  Average frequency of ecstasy consumption ranged from 1.44 to 14.8 tablets per month.  
Average number of years participants consumed ecstasy spanned from 0.2 to 14.7 years.  See 
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Table 2 for information about participant ecstasy use by study.    Studies varied in the degree to 
which the control group matched the ecstasy use group on other substance use (see Table 3) and 
possible moderating demographic variables (i.e., intelligence, education level, age; see Table 4).  
The meta-analysis included studies representing a broad range of samples in order to increase the 
generalizability of the findings and reduce possible bias associated with eliminating a large 
amount of published data (Rosenthal & DiMatteo, 2001).   
Extracting effect sizes from primary studies 
Effect sizes for each primary study were computed using Hedge’s g. The standardized 
mean difference is commonly used when comparing the means from two groups, as in the 
present meta-analysis that compares the means of measures of cognitive performance between 
ecstasy consumers and ecstasy naïve controls.  The standardized mean difference, however, 
tends to be upwardly biased in samples smaller than 20.  Hedge's g is also based on the 
standardized difference between two means.  It is equal to the difference between the means 
divided by the pooled standard deviations of the two samples.  The result is the number of 
standard deviations that separates the means of the two samples.  In contrast to the standardized 
mean difference, Hedge's g does not overestimate the difference between means in small samples 
(Hedges, 1981; Lipsey & Wilson, 2001).  Although r is a favorite effect size measure for meta-
analysts due to ease of interpretation by social scientists (Rosenthal & DiMatteo, 2001), Hedge’s 
g is more appropriate for the difference between two groups on cognitive performance, 
particularly considering the common use of standardized scores in cognitive assessment and 
interpretation (Lezak, 1995).   
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Computed effect sizes were limited to the differences between two groups, ecstasy 
consumers and ecstasy naïve controls.  Primary studies frequently compared multiple groups of 
participants, including variations of control groups (i.e, non-substance users, marijuana 
consumers, ecstasy consumers), multiple durations of abstinence, and multiple levels of 
historical quantities of ecstasy use (i.e., heavy users, light users).   Effect sizes based on 
differences between means in meta-analysis are limited to comparisons in primary studies in 
which degrees of freedom are equal to one.  F tests with df > 1 indicate that there is a difference, 
but do not indicate directionality (Hedges, 1994).  Inclusion of effect sizes resulting from 
multiple pairwise comparisons using various combinations of the same groups leads to error due 
to dependence (Hedges & Olkin, 1985).  Therefore, if a study included comparisons with 
multiple control groups (i.e., poly-substance users and non-substance users), the control group 
that most resembled the ecstasy group on other drug use was selected.   This selection procedure 
was used for all studies except one.  For one study  (Croft et al., 2001), it was necessary to use 
the non-substance user control group because some members of the marijuana using control 
group reported that they also used ecstasy.  Therefore, the marijuana using control group did not 
meet the inclusion criteria for the meta-analysis.   If a study included multiple time points with 
the same participants and same measures, the first measurement session was used to minimize 
influence of practice effects.  If a study included former users and current users, results from the 
former consumers were used, to minimize the contribution of drug withdrawal.  If a study 
included groups of heavy and light users and combined group information was not included in 
the manuscript, information from heavy users was used to compute effect size.  Heavy users 
were selected to maximize the chances of participants having used a sufficient amount of ecstasy 
to produce a noticeable difference.   If a study experimentally compared the effects of an 
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intervention in ecstasy users and ecstasy naïve controls, results of cognitive measures completed 
before the experimental intervention were used to compute effect sizes.    
Most primary studies included in the meta-analysis used multiple measures of cognitive 
performance.   Few primary studies used the same assessment instruments or the same 
combinations of cognitive measures.  Selection of any one measure as representative of the data 
from the primary studies would have been arbitrary and possibly would open an opportunity to 
introduce bias.  Thus, with few exceptions, results from all measures from the included primary 
studies that assessed attention, verbal memory, nonverbal memory, executive functioning, 
fluency, reaction time, or learning were included in the meta-analysis.  Exceptions were made for 
the following circumstances.  Hanson & Luciana (2004) used the Affective Working Memory 
(Luciana, Burgund, Berman, & Hanson, 2001) measure.  The measure used stimuli with affective 
content that has been found to produce differential performance in people who have had their 
brain levels of 5-HT manipulated in laboratories.  The MDMA group in Hanson & Luciana’s 
(2004) study was significantly more depressed than the control group.  As the measure, Affective 
Working Memory, may be confounded by differences in affective functioning and differences in 
affective functioning is not the hypothesis currently being tested, the effect sizes from the 
Affective Working Memory measure were not included in the meta-analysis.  Bond and 
colleagues (2004) used a reading measure that was similarly confounded by affective content.  
Only the results from the measure that used non-affective content were used in the meta-analysis.  
Finally, the mean for one measure in one study was likely misreported.  The reported mean 
would result in different statistical results than what was reported in the table in the primary 
study manuscript.  Consequently, the effect size for LGT-3 Library delayed recall from the study 
conducted by Gouzoloulis and colleagues (2003) was not included in the analysis. 
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Using more than one outcome effect size from a single sample within a study gives too much 
weight to the results of the study.   Treatment of dependent outcomes as if they were derived 
from independent primary studies could inflate the sample size of the meta-analysis, obscure an 
estimate of error, and increase the chance of committing a Type I error (Wolf, 1986).  
Fortunately, when a study contributes more than one effect size for outcomes, they can be used 
individually in subgroup meta-analyses and they can be combined in a manner that does not 
inflate sample size to complete an investigation of the overall relationship (Rosenthal & 
DiMatteo, 2001).  
The present meta-analysis combined data using a computer program, Comprehensive 
Meta-analysis, developed through funding by the National Institutes of Health by a panel of 
researchers with extensive knowledge of meta-analysis (i.e., Michael Borenstein, Larry Hedges, 
Harris Cooper, etc.).   Comprehensive Meta-analysis combines multiple outcomes measured 
within the same sample by computing an average.  This is a common method of preventing 
sample size inflation inherent in treating multiple outcomes from the same study as independent 
(Lipsey & Wilson, 2001; Rosenthal & DiMatteo, 2001).  In computing an average of the 
variances, it is assumed that the correlation among the outcomes is zero.   Measures of cognitive 
functioning are often correlated.  Therefore, the estimated standard error provided by averaging 
is likely larger than the correct standard error, thereby decreasing the chance of rejecting the null 
hypothesis (personal communication Michael Borenstein, July 8, 2005).  The greater the 
intercorrelations, the less chance of rejecting the null hypothesis.  To prevent underestimation of 
effect size, computation of a composite score that weights dependent outcomes by their 
covariance has been recommended (Rosenthal & Rubin, 1986) and it has been found that the 
composite method produces larger effect sizes than does simple arithmetic averaging (Marin-
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Martinez & Sanchez-Meca, 1999).   Without access to the original data, however, it is not 
possible to generate the intercorrelations between the outcomes and the practical utility of 
computing the composite score is reduced (Lipsey & Wilson, 2001).  Some researchers have 
recommended estimating the intercorrelations to create a composite effect size that takes into 
account covariance (Rosenthal & Rubin, 1986), but it is unclear if the estimations provide a more 
true result.   Some combinations of cognitive measures are more intercorrelated than others.  The 
amount of intercorrelation among outcomes within one primary study may be substantially 
different than the intercorrelation among outcomes within another primary study, particularly 
when primary studies include a multitude of different combinations of outcome measures.  Thus, 
incorrect estimates of the intercorrelations may add another source of error and increase the 
chance of spuriously rejecting the null hypothesis.   The present procedure takes the more 
conservative approach of averaging the dependent outcomes (Rosenthal & DiMatteo, 2001).  In 
interpretation, it should be remembered that the effect size is likely attenuated, however, the risk 
of Type I error is low.   
Effect sizes from primary studies were not assigned weights by methodological quality.  
Methodological quality can affect the primary study outcome in unpredictable ways and there is 
not a theoretically sound, specific weighting method that would increase the chance of attaining 
a less biased estimate of the population parameter (Shadish & Haddock, 1994).   Rather, 
methodological quality of the primary studies was addressed in the study selection process (see 
description provided earlier in the paper) and in coding of various methodological aspects for 





Most primary study manuscripts included in the meta-analysis provided enough 
information to compute effect sizes for all relevant results.  Only 4 included studies provided 
information for computing effect sizes for significant results, but failed to provide information 
for non-significant results (Curran & Verheyden, 2003; Fox et al., 2002; Reneman, Lavalaye, & 
Schmand 2001; Wareing et al., 2000).  Some meta-analysts have recommended assigning an 
effect size equal to zero when a primary study manuscript indicates that an effect size was not 
statistically significant, but provides insufficient information to compute an effect size 
(Rosenthal & DiMatteo, 2001).  Statistical significance, however, is based on the difference 
between the group distributions and the sample size. If the sample is not sufficiently large, an 
effect size that departs from zero may not be found to be statistically significant. Differences in 
distributions that would be found to be statistically significant in a large sample may fail to reach 
statistical significance if the sample size is small.  Furthermore, an effect size with an associated 
p value of .06 is more different from zero than is an effect size with an associated p value of .50, 
if the sample size is the same.  While problems are introduced by including only those effect 
sizes for which sufficient information exists in the primary study manuscripts, additional 
problems are caused by arbitrarily assigning an effect size of zero.   The present meta-analysis 
does not assign an effect size of zero as a replacement for missing data.  Instead, the data are 
treated as missing and Rosenthal’s (1979) fail safe N is used to compute the number of studies 




Assessing publication bias  
As nonsignificant results are less likely to be published (Rosenthal, 1979) and, when 
nonsignificant results are published, authors are less likely to include information that can be 
used to compute an effect size, there is an increased the possibility that any published result is a 
false positive (Begg, 1994).  A funnel plot was graphed to investigate the likelihood of 
publication bias.  The graph plots size of the effect by standard error under the assumption that 
large studies are more likely to be published than are small studies, regardless of effect size and 
small studies with large effect sizes are more likely to be published than are small studies with 
small effect sizes (Begg & Mazumdar, 1994).   Large effect sizes that result from small studies 
are more likely to be due to sampling error than are large effect sizes in large samples. Larger 
studies at the top of the funnel plot should tend to cluster about the aggregate effect size, if the 
effect size is a reasonable estimate of the population effect size.  Small studies plotted at the 
bottom of the graph should show a wider spread about the aggregate effect size.  A chunk 
missing in one lower corner suggests publication bias (Greenhouse & Iyengar, 1994).  To 
provide an estimate of how confident the reader can be in the aggregated results of the included 
studies, Rosenthal’s (1979) fail safe N was calculated as an estimate of the number of missing 
studies required to reject the null hypothesis. 
Estimating the magnitude of the relationship between ecstasy use and cognitive performance 
An estimate of the magnitude of the relationship between ecstasy use and general 
cognitive performance was achieved by pooling the weighted effect sizes that represented the 
average of the results from all cognitive measures from each primary study.  The overall estimate 
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is the combination of many forms of cognitive assessment from participants with a variety of 
ecstasy use patterns and in a variety of nations.  Although some critics have spoken against 
combining the results of studies that differ in a number of ways, it has been proposed that, “It is a 
good thing to mix apples and oranges, particularly if one wants to generalize about fruit” (p. 68, 
Rosenthal & DiMatteo, 2001).  Exact replications of studies limit the generalizability of results.  
Using multiple studies that measure the construct in a variety of ways increases the external 
validity of the conclusions and the construct validity of the latent variable. Robust findings are 
indicated when they remain constant through a variety of samples and operational definitions 
(Hedges, 1994).   In addition to achieving an overall estimate, sub-analyses of the following 
cognitive domains were conducted: attention, immediate verbal memory, delayed verbal 
memory, immediate nonverbal memory, delayed nonverbal memory, executive functioning, 
fluency, reaction time, and learning.  Performing multiple meta-analyses for each type of 
outcome variable enhances the interpretation of the results by permitting investigation of the 
differential relationships dependent on outcome domain (Kulik, 1983; Rosenthal, 1984).  
Conducting nine sub-analyses would increase the chance of making a Type I error to 36.98%, if 
the null is rejected at p < .05 for each comparison.  Therefore, the results of sub-analyses are 
presented with their corresponding p value and a Bonferroni adjustment was used to set the one-
tailed Zcritical = - 2.128.  The Bonferroni adjustment was computed using Dubey, Armatige, and 
Parmar’s formula for modifying Bonferroni for correlated outcomes (Sankoh, Huque, & Dubin, 
1997).  A one-tailed Zcritical was selected because it was hypothesized that ecstasy users would 
have more impaired cognitive performance than would ecstasy naïve controls.  Readers 
concerned about Type II error may refer to p values provided in the tables describing the results 
and draw their own conclusions.   
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 Both fixed effects and random effects models were used to calculate the overall effect 
size and the effect sizes by domain.  The fixed effects model assumes that the differences in 
effect sizes between primary studies are attributed solely to participant-level sampling error.  The 
random effects model assumes that there are different population effect sizes depending on 
characteristics of the primary studies.  The differences in effect sizes are attributed to both study-
level sampling error and participant-level sampling error (Hedges, 1994; Lipsey & Wilson, 
2001). Fixed effects models provide more powerful tests of the overall null hypothesis, but 
results based on the fixed effect model cannot be generalized to studies other than those included 
in the sample.  The random effects model permits generalization outside of the studies included 
in the analysis (Rosenthal & DiMatteo, 2001).   The fixed effects model can be used if the true 
effects sizes are invariant or if their variance is predicted by identified study characteristics with 
no remaining unexplained variance.   If true effect sizes vary as a function of unmeasured study 
characteristics, it is advisable to use the random effects model.  The random effects model 
acknowledges lack of identified sources of variance by treating differences as random.  
However, it is still advisable to explore possible sources of systematic variance (Raudenbush, 
1994; The Cochrane Collaboration, 2005).  Accordingly, when significant heterogeneity exists in 
effect sizes, conclusions are based on the random effects model and sources of heterogeneity are 
investigated.    
Homogeneity suggests that there is a single population parameter that is estimated by the 
aggregate effect size.  Heterogeneity poses the potential that there are multiple population 
parameters dependent on study or participant characteristics.  Homogeneity was evaluated using 
I2 and the Q statistic with a chi-square test of significance.  Degrees of freedom for the Q statistic 
are k -1, where k is the number of primary studies included in the analysis.  As the significance 
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of the Q statistic is affected by sample size, other methods of heterogeneity investigation were 
also used.  Heterogeneity was also assessed by comparing the aggregate effect size estimates 
resulting from the application of the fixed versus random effects models and by inspecting the 
amount of overlap in confidence intervals of primary study effect sizes.  If there is little overlap 
in the confidence intervals for the results of the individual primary studies, the results are likely 
heterogeneous (Hedges & Olkin, 1985; Higgins & Thompson, 2002; The Cochrane 
Collaboration, 2005).   
Investigating potential sources of heterogeneity 
Tests of heterogeneity examine the likelihood that differences between effect sizes are 
due to sampling error or that there is likely some systematic variance among effect sizes that may 
be attributed to moderator variables (Hedges, 1994).   Variability among effect sizes indicates 
that influences of possible moderating variables should be investigated.  When searching for 
moderators, Rosenthal and DiMatteo (2001) recommend using an explorative, rather than a 
confirmative approach, to contribute to theory development and identify areas for further study.   
An exploratory process was used in sensitivity analyses, but a priori identified potential 
moderators were investigated (see hypotheses listed earlier in the paper).  As significant 
heterogeneity exists in the primary studies, the method of unrestricted maximum likelihood for 
mixed effects regression was used to test possible moderating variables identified as continuous 
variables (Raudenbush, 1994).  Sensitivity analyses were performed to test the potential that the 
resultant overall effect size was dependent on the study inclusion criteria and to explore possible 
sources of heterogeneity.  As a portion of the sensitivity analysis, aggregated effect sizes were 
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repeatedly calculated with each study removed once per calculation.  This was done to determine 
if inclusion of any one study had a large impact on the aggregate effect size estimate 
(Greenhouse & Iyengar, 1994).  
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RESULTS 
Analysis of combined cognitive domains 
An overall effect size for all included cognitive domains combined across the sample of 
37 studies was estimated using the fixed effects model, ES = -0.50, CI (-0.60 to -0.40), Z = -6.22,  
p = .000 (see Table 5).   The effect sizes for most primary studies were in the predicted direction; 
however, inspection of the Forrest plot (see Figure 1) revealed that there was variance in the 
magnitude of the effect and the 95% confidence intervals for a number of the primary study 
effect sizes crossed zero.  There was statistically significant heterogeneity across study effect 
sizes, I 2= 57.27, Q (36) = 84.25, p = .000 (see Table 6).  Therefore, the overall effect size using 
the random effects model was inspected.   It was statistically significant, ES = -0.52, CI (-0.60 to 
-0.40), Z = -6.22,  p = .000, and was similar to the effect size based on the fixed effects model 
(see Table 5).  The overall effect size using the random effects model is a moderate effect size 
and roughly corresponds to a correlation of 0.3 (Cohen, 1988).     
Assessing the potential for publication bias 
Inspection of the funnel plot (see Figure 2) for the present meta-analysis suggested that 
there is a degree of publication bias in the estimated aggregate effect size.   If no publication bias 
existed, a larger number of small studies that found no relationship between ecstasy use and 
cognitive performance would have been published and available for inclusion in the meta-
analysis. As publication bias was suggested by the funnel plot, Rosenthal’s (1979) fail safe N 
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was computed.  The fail safe N for the overall effect size was 850 studies.  The fail safe N 
indicates the number of missing studies with an effect size of zero that would need to be included 
in the meta-analysis to bring p above .05.   
Sub-analyses for each cognitive domain 
Sub-analyses for each cognitive domain were conducted (see Table 7).  All aggregate 
effect sizes for cognitive domains were in the predicted direction, with the ecstasy use group 
performing worse than the ecstasy naïve control group.  Significant aggregate effect sizes for 
attention, immediate verbal memory, delayed verbal memory, immediate nonverbal memory, 
delayed nonverbal memory, executive functioning, fluency, and reaction time were found, 
Zobserved < -2.128.  The aggregate effect size for learning was not statistically significant, Zobserved 
= -1.349. Comparison of Z and p values among sub-analyses is less informative than is 
comparison of effect size values, as Z and p values are influenced by sample size and the number 
of studies included in each sub-analysis differs.  Comparison of aggregate effect sizes suggested 
that the strongest relationships between ecstasy use and cognitive performance were found in 
measures of delayed verbal memory, ES = -0.88, CI (-1.50 to -0.26), Z = -2.77,  p = .006, 
immediate verbal memory, ES = -0.63, CI (-0.85 to -0.41), Z = -5.65,  p = .000, and delayed 
nonverbal memory, ES = -0.63, CI (-1.15 to -0.11), Z = -2.39,  p = .000. 
Heterogeneity 
 Heterogeneity for the overall effect size for combined cognitive domains, the sub-
analyses of each cognitive domain, and the sensitivity analyses was evaluated using I2, the Q 
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statistic with a chi-square test of significance.  I2 is the percentage of the variability in the effect 
size estimates that is attributed to heterogeneity as opposed to participant-level sampling error 
(Higgins & Thompson, 2002).  Heterogeneity statistics can be found in Table 6.  Significant 
heterogeneity was found in the overall effect size for combined cognitive domains and in most of 
the sub-analyses for each cognitive domain, with the exception of executive functioning, I 2= 
21.84, Q (12) = 15.35, p = .223, and learning, I 2= 0.00, Q (7) = 4.55, p = .714.  It should be 
remembered that the significance of the chi-square test for Q depends upon sample size.  It can 
result in highly significant values despite little variation among effect sizes when the sample size 
is large (Rosenthal & DiMatteo, 2001; The Cochrane Collaboration, 2005).   Inspection of 
Forrest plots and effect sizes for each primary study provides further indications of heterogeneity 
and can sometimes suggest sources of heterogeneity.  A Forrest plot for the analysis of the 
overall effect size for combined cognitive domains is presented in Figure 1.  Forrest plots for 
sub-analyses and sensitivity analyses are presented in Figures 3 through 15.  Inspection of the 
Forrest plots and primary study effect sizes suggested that effect sizes for each cognitive domain 
were generally in the predicted direction.  This suggested that most of heterogeneity was due to 
differences in the magnitude of the effect sizes, as opposed to differences in the direction of the 
effect sizes.  However, there were infrequent disparate findings and most of the 95% confidence 
intervals for effect sizes crossed zero.   
Investigation of potential moderating variables 
Heterogeneity suggests the influence of at least one moderator.   A priori hypothesized 
moderators were tested.  As there was uneven reporting of moderator variable information in the 
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primary studies (see Table 2), separate meta-regression analyses were conducted for each 
potential moderator variable.  A Bonferroni adjusted Zcritical of +/- 2.569 was used to protect 
against experiment-wise error.  A two-tailed test was selected since it was anticipated that some 
moderators would be negatively related and some would be positively related to effect size.   
 Amount of ecstasy consumed was measured by three variables: self-reported total 
lifetime cumulative ecstasy use, self-reported frequency of ecstasy use per month, and self-
reported total number of years ecstasy was used.   The three measures of amount of ecstasy 
consumed and the duration of abstinence from ecstasy before cognitive assessment were tested in 
four separate mixed effects regression analyses using the method of unrestricted maximum 
likelihood (see Table 8).  Results failed to support a relationship between total lifetime 
cumulative ecstasy use and effect size, Qmodel  = 0.17, Qtotal  = 30.39, Z = -0.42,  p = 0.677, (see 
Figure 16).   Seven studies were not included in the meta-regression because average total 
lifetime cumulative ecstasy use was not reported in the manuscripts.  Results supported the 
relationship between reported frequency of ecstasy use per month and effect size, slope point 
estimate = -0.09, Qmodel  = 33.60, Qtotal  = 61.04, Z = -5.80,  p = 0.0000 (see Figure 17).    
Seventeen studies were not included in the meta-regression because frequency of ecstasy use was 
not reported in the manuscripts.  Results failed to support a relationship between number of years 
ecstasy was used and effect size, Qmodel  = 3.22, Qtotal  = 28.95, Z = 1.79,  p = 0.073, (see Figure 
18).   Ten studies were not included in the meta-regression because information about the 
required duration of abstinence was not quantified and reported in the manuscripts.  The 
Cochrane Collaboration (2005) recommends conducting sensitivity analyses of meta-regressions 
by testing with and without extreme scores.  As an extreme score may have influenced the results 
of the meta-regression, data from Zakzanis and colleagues’ (2002) study was removed and the 
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analysis was repeated.  Results continued to fail to support a relationship between number of 
years ecstasy was used and effect size, Qmodel  = 2.11, Qtotal  = 27.98, Z = 1.45,  p = 0.146, (see 
Figure 19).   Finally, results failed to support a relationship between duration of required 
abstinence from ecstasy and effect size, Qmodel  = 0.33, Qtotal  = 35.59, Z = -0.57,  p = 0.567, (see 
Figure 20).   Two studies were not included in the meta-regression because information about the 
required duration of abstinence was not reported in the manuscripts.  Although a substantial 
proportion of the heterogeneity could be attributed to a potential dose-response relationship (i.e., 
frequency of ecstasy use per month), a large amount of heterogeneity remained (see Table 8).   
Sensitivity analyses 
Sensitivity analyses were conducted to investigate the potential influence of study 
inclusion criteria on aggregate effect size estimates.    The sensitivity analyses were exploratory.  
Accordingly, no adjustment was made to Zcritical to control for experiment-wise error.   
Primary studies restricted participant inclusion criteria for control groups in a variety of 
ways.  Sensitivity analyses in the form of sub-analyses divided by other substance use of control 
group were conducted (see Table 9).  As control group substance use increased, aggregate effect 
size for the relationship between ecstasy use and cognitive performance approached nil, but 
remained in the predicted direction.  The aggregate effect sizes were statistically significant for 
all but the sub-analysis of primary studies exclusively using polysubstance users in the control 
groups, ES = -0.25, CI (-0.573 to 0.074), Z = -1.511,  p = .131.  Results for the sub-analysis of 
the primary studies using polysubstance consumer control groups were the same for the fixed 
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and random effects models due to homogeneity of primary study effect sizes (see graphic display 
of fixed and random effects point estimates and confidence intervals in Figure 15). 
Heterogeneity statistics suggested that differences in primary study effect sizes for the 
sub-analysis limited to control groups consisting of polysubstance consumers could be explained 
by participant-level sampling error, I 2= 0.00, Q (3) = 0.07, p = .996.  Heterogeneity of primary 
study effect sizes for the sub-analysis limited to control groups consisting of marijuana 
consumers could also likely be explained by participant-level sampling error, I 2= 0.00, Q (5) = 
1.89, p = .864.  To a lesser degree, support was found for the homogeneity of primary study 
effect sizes for the meta-analysis limited to control groups consisting of non-substance users, I 
2= 42.96, Q (4) = 7.01, p = .135.  The homogeneity of primary study effect sizes was not 
supported for the sub-analysis limited to control groups consisting of a mixture of non-substance 
users and participants who used a variety of substances, I 2= 57.30, Q (17) = 39.81, p = .001 (see 
Table 6).  This suggests that study-level sampling error may influence the aggregate effect size 
for this sub-analysis.   When study-level sampling error is likely, it is advisable to interpret 
results from the random effects model.  The results from the random effects model will resemble 
the results from the fixed effects model to the degree that homogeneity is present (The Cochrane 
Collaboration, 2005).  Accordingly, the effect sizes for the random effects model are presented in 
Table 9 for comparison among sub-analyses.  Heterogeneity as well as graphic displays of point 
estimates and confidence intervals for both fixed and random effects models can be found in the 
Forrest plots in Figures 12 through 15.   
 Only 3 primary studies reported that the differences between the ecstasy use groups and 
the ecstasy naïve control groups on alcohol, marijuana, and other drug use were not statistically 
significant.  The remainder of the studies tested the statistical significance of the differences 
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between the groups on fewer than all three variables, reported that one group used more than the 
other, or failed to provide information about the substance use of the control group.  In 19 of the 
primary studies, the ecstasy use group used more marijuana, alcohol, or other drugs than did the 
ecstasy naïve control group (see Table 3).   
A sensitivity analysis was conducted using only studies with control groups known to be 
balanced for alcohol, marijuana, and other drug use.  The analysis was conducted because 
independent studies have found that alcohol, marijuana, and other drug use can influence the 
results of cognitive assessment (Verdejo-Garcia, et al., 2004).  The resultant aggregate effect size 
estimate was in the predicted direction, but was not of sufficient magnitude to reach statistical 
significance, ES = -0.34, CI (-0.763 to 0.087), Z = -1.558,  p = .119 (see Table 9).  Results were 
the same for the fixed and random effects models, due to homogeneity of primary study effect 
sizes, I 2= 0.00, Q (3) = 0.96, p = .620 (see Table 6).  Graphic displays of point estimates and 
confidence intervals for both fixed and random effects models can be found in the Forrest plot in 
Figure 21.  Note that two out of the three studies included in the sensitivity analysis were from 
the same laboratory and were completed within approximately the same timeframe.  Results of 
this sub-analysis should be interpreted with caution due to the small number of studies included 
in the analysis and the dependence in effect sizes between the two studies completed close in 
time and space.   
In 11 primary studies, differences between the ecstasy use groups and the ecstasy naïve 
control groups on general intelligence, education, and age were reported to be found to not be 
statistically significant (see Table 4).  As general intelligence, education, and age can influence 
the results of cognitive assessment (Lezak, 1995), a sensitivity analysis was conducted using 
only studies with control groups known to be balanced for these variables.  When the control 
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groups were balanced for general intelligence, education, and age, the effect size computed under 
the fixed effects model remained statistically significant and was in the predicted direction, ES = 
-0.42, CI (-0.577 to -0.254), Z = -5.036,  p = .000.  A significant amount of heterogeneity was 
found in the effect sizes of the included primary studies, I 2= 73.99, Q (11) = 38.44, p = .000 (see 
Table 6 and Figure 22).  Consequently, results of the random effects model were interpreted.  
The aggregated effect size computed under the random effects model remained statistically 
significant and was in the predicted direction, ES = -0.35, CI (-0.678 to -0.017), Z = -2.061,  p = 
.039. 
To test the sensitivity of the combined effect size estimate to the influence of individual 
primary studies, the overall effect size for combined cognitive domains was calculated with one 
study removed per calculation (Greenhouse & Iyengar, 1994).  As would be expected, given the 
sample size of the study (ecstasy use group n = 100, control group n = 100), Yip & Lee (2005) 
had the largest influence on effect size.  With Yip & Lee (2005) removed, the aggregate effect 
size remained statistically significant and continued to be moderate in magnitude, but was 
slightly reduced, ES = -0.47, CI (-0.61 to -0.32), Z = -6.20,  p = .000, see Table 10.   A Forrest 
plot of the one study removed sensitivity analysis is presented in Figure 23.   
One study removed sensitivity analyses were also conducted for sub-analyses of each 
cognitive domain.  Results can be found in Tables 11 through 19.  Removing any one study did 
not greatly affect the results of sub-analyses for measures of attention, immediate verbal 
memory, immediate nonverbal memory, fluency, or reaction time.  However, influences of single 
studies were evident within other cognitive domains.  Removing Yip & Lee (2005) from the 
aggregate estimate of the effect size for measures of delayed verbal memory did not change the 
significance of the aggregate effect size, but substantially reduced the magnitude of the estimate, 
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ES = -0.58, CI (-0.85 to -0.30), Z = -4.09,  p = .000 (see Table 13).   Removing McCann and 
colleagues’ (1999) study from the aggregate effect size for measures of delayed nonverbal 
memory and removing Gouzoulis-Mayfrank and colleagues’ (2000) study from the aggregate 
effect size for measures of executive functioning increased the p values above .05 and the Z 
values above the Bonferroni adjusted Zcritical value of -2.128 (see Tables 15 through 16).  
Removing Back-Madruga and colleagues’ (2003) study from the aggregate effect size for 
measures of learning decreased the p value to below .05, but the Z value remained above the 
Bonferroni adjusted Zcritical value of -2.128 (see Table 19). 
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 DISCUSSION  
 The present study used meta-analysis to combine the results of the empirical literature on 
the non-acute cognitive sequelae of recreational ecstasy use.  Meta-analysis provides a powerful 
test of the relationship between two variables.  Similar results repeated over many studies, even 
if not statistically significant within the primary studies, provide stronger evidence of a 
relationship than does one study with a statistically significant result (Rosenthal & DiMatteo, 
2001).  The resultant overall effect size for combined cognitive measures suggests a moderately 
strong relationship between non-acute recreational ecstasy use and cognitive performance.  The 
overall effect size of -0.52 CI (-0.60 to -0.40) indicates that participants in the ecstasy use groups 
performed, on average, a little over one-half of a standard deviation below the performance of 
ecstasy naïve participants on combined measures of cognitive functioning.  In addition, small to 
large, statistically significant aggregate effect sizes resulted for eight of nine cognitive ability 
domains included in the analysis.  The one exception was the aggregate effect size for learning.  
Although the aggregate effect size for measures of learning was in the predicted direction, the 
95% confidence interval crossed zero, indicating that the null hypothesis could not be rejected.  
Results of the present meta-analysis are consistent with animal studies that show serotonergic 
neurotoxicity as a result of exposure to MDMA (Steele et al., 1994; Lyles & Cadet, 2003).  They 
are also consistent with results of functional neuroimaging studies that locate lesions associated 
with ecstasy use in areas of the brain that are involved in attention, memory, and executive 
functioning (Hurley, Reneman, & Taber, 2002).  Finally, they are consistent with studies that 
correlate ecstasy-related serotonin deficits with cognitive functioning (McCann et al., 1994).  
 34
Effect sizes varied as a function of reported frequency of ecstasy use per month, but were 
not moderated by other indications of ecstasy exposure (i.e., total lifetime cumulative ecstasy 
use, years of ecstasy use).  Effect sizes were also not moderated by duration of abstinence before 
cognitive testing. This is inconsistent with some empirical findings that have previously been 
published (Steele et al., 1994; Thomasius et al., 2003).  However, a recently published 
longitudinal study comparing the cognitive performance of former ecstasy users to continuing 
ecstasy users also found no recovery of functioning in the abstinent ecstasy users (Gouzoulis-
Mayfrank et al., 2005).  That no recovery of functioning was evident suggested that the cognitive 
sequelae are not limited to possible ecstasy withdrawal symptoms.  Only a small number of 
studies were conducted in which a minimum of one year of abstinence was required before 
testing.  It is possible that that the relationship between duration of abstinence and cognitive 
functioning would be found if more studies were conducted with one year or longer required 
abstinence periods. 
Findings were complicated by differential effect sizes identified in sensitivity analyses 
when various study inclusion criteria were used. Inspection of the effect size estimates based on 
subgroups of studies divided by type of control group (see Table 9) suggested that the relative 
cognitive impairment found in ecstasy users was confounded by the amount of other drugs used 
by the control group. As substance use (other than ecstasy) of control group increased to match 
substance use of the ecstasy use group, the effect size for the relationship between ecstasy use 
and cognitive performance approached the nil (see Table 9).  It did not reach zero, but became 
statistically non-significant. Care should be taken in comparing the p values in the sensitivity 
analyses, as p is strongly related to sample size and there were differences in the number of 
studies that used the various types of control groups.  The sensitivity analysis that included 
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control groups consisting exclusively of polysubstance users involved aggregating the results of 
only four primary studies. Consequently, conclusions based on the non-significance of the 
finding should be made with extreme caution.  The lower the number of primary studies included 
in a meta-analysis, the less powerful the test of the null hypothesis and there is a greater chance 
of committing a Type II error (Rosenthal, 1984).  Additional studies are needed to verify the 
results of this sub-analysis.  If the null hypothesis was correctly rejected, it does not rule out a 
relationship between ecstasy use and impaired cognitive performance.  Non-acute other 
substance use has been found to impair cognitive performance (Verdejo-Garcia, et al., 2004).  
The hypothesis tested in the present study was not that ecstasy use would be related to more 
severe cognitive impairment than other drug use, but that it would be related to impaired 
cognitive performance.  That the effect size remained in the predicted direction is notable.  
When the control groups included only marijuana users, there continued to be a 
statistically significant effect size in the predicted direction.   This suggested that impaired 
cognitive performance associated with ecstasy use could not be completely explained by 
concomitant marijuana use. The effect size, however, was attenuated.  Some might conclude that 
the attenuated effect size is evidence that concurrent marijuana use might reduce the risk of 
neurotoxic ecstasy effects (Parrot, et al., 2004).  It is more likely that the control group was 
experiencing cognitive impairment related to marijuana use and, therefore, performed more like 
the ecstasy use group.  While the evidence of sustained cognitive sequelae of marijuana use is 
inconsistent at best (Grant, Gonzalez, Carey, Natarajan, & Wolfson, 2003), there is evidence that 
chronic marijuana consumers experience associated cognitive impairment during a period of 
withdrawal (Pope, Gruber, Hudson, Huestis, & Yurgelun-Todd, 2001).   
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The strongest effect size was found in comparisons between ecstasy users and non-drug 
users.  Using non-drug users as the control group introduces the confound that other drug use 
may be responsible for the difference between the two groups.  As ecstasy users seldom 
exclusively use ecstasy (e.g., Morgan, 1999; Parrott et al., 2000), it is more appropriate to use a 
control group that is matched with the ecstasy use group on other substance use.  Although 5 
primary studies used participants without experience using other drugs in the control groups, 
only 3 studies demonstrated that the other drug use of the control group was not statistically 
significantly different from the other drug use of the ecstasy use group (see Table 3).  A 
sensitivity analysis including only the studies that were balanced on alcohol, marijuana, and 
other drug use resulted in an effect size in the predicted direction, but failed to reach statistical 
significance.  Again, the results of the sub-analysis should be viewed with extreme caution as 
they were based on the aggregation of 3 primary studies.  Additional caution is warranted given 
that 2 of the 3 studies were completed in the same laboratory at around the same timeframe. 
Findings of sensitivity analyses highlight the importance of cautious inclusion and 
exclusion criteria for participants in observational studies of the consequences associated with 
recreational ecstasy use.  To reduce the potential confound of cognitive impairment arising from 
other substance use, future researchers may wish to focus data collection on participants with 
less severe other substance use and on a control group that is carefully matched on other 
substance use to the ecstasy use group. In addition, if there is substantial other drug use in the 
control group, researchers may wish to increase their sample size because the resultant effect size 
will likely be attenuated.   Findings of the present meta-analysis suggest that, although it is likely 
that the magnitude of the effect size will change as a result of degree of inclusion of participants 
with other substance use, the direction of the effect size is likely to remain the same. 
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 The present meta-analysis is a replication and extension of a meta-analysis of the long 
term cognitive sequelae of ecstasy use completed in 2002 (Verbaten, 2003).  The present meta-
analysis improved upon the previous analysis by including more of the outcome data from the 
studies that were used in the previously conducted meta-analysis.  Verbaten (2003) selected one 
to four outcomes per study.  The present meta-analysis included all relevant outcomes, 
permitting greater confidence that selection of which outcome to include did not bias the results.  
The present meta-analysis also included studies that were not published at the time of the 
previous meta-analysis, thereby enabling additional sub-analyses within the present meta-
analysis of cognitive domains that were not included in the previous meta-analysis.  Inclusion of 
more studies also permits greater confidence in the results of the meta-analysis.  Whereas the 
highest fail safe N is Verbaten’s (2003) study was 14, the fail safe N in the present meta-analysis 
was 850.  Results of the present meta-analysis are similar to what was found in the former meta-
analysis.  In the present meta-analysis, the aggregate effect sizes for immediate verbal memory 
and delayed verbal memory were found to be -0.63 and -0.88 respectively.  Verbaten (2003) 
estimated the effect sizes for immediate verbal memory and delayed verbal memory to be -1.15 
and -1.36 respectively.  Significant heterogeneity was found in the effect sizes from the primary 
studies included in both the previous and present meta-analysis.  Heterogeneity suggests the 
presence of study-level sampling error.  When the potential for sampling error exists, a large 
sample size produces a better estimate of the population parameter.  On the basis of sample size, 
the present meta-analysis was more likely to produce an estimate that was closer to the 
population parameter (Rosenthal, 1984).  Furthermore, although Verbaten (2003) reported that 
significant heterogeneity existed in the aggregate effect size estimates produced in the analysis, 
few sensitivity analyses were conducted to identify possible sources of study-level selection bias.  
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The present meta-analysis conducted a number of sensitivity analyses to address the potential 
that inclusion criteria influenced the results.  Finally, Verbaten (2003) questioned the possible 
causal relationship between ecstasy use and impaired cognitive performance on the basis that 
total lifetime cumulative ecstasy use was not found to be related to effect size in the previously 
conducted meta-analysis.  No other possible dose-response relationships were investigated in the 
previous meta-analysis.   
While the present meta-analysis also did not find a relationship between total lifetime 
cumulative ecstasy use and effect size, reported frequency of ecstasy use per month was 
identified as a statistically significant moderating variable.  It is possible that the relationship 
between total lifetime cumulative ecstasy use and effect size was attenuated by low reliability in 
self-reported lifetime cumulative use.  Although the reliability of self-reported total lifetime 
cumulative use was not tested in the present study, it is possible that participants were able to 
better estimate how much ecstasy they typically consume within a month than they were to 
correctly estimate the total number of tablets they have taken.  Consider that mean estimates of 
lifetime use were in the hundreds and, in one study, was more than 1000 tablets (see Table 2).   
Only a small number of studies included participants with total lifetime cumulative ecstasy use 
over 500 tablets.  It is possible that a relationship would be found if more studies recruited 
participants with very high cumulative use.  It is notable, however, that large effect sizes were 
found in studies with total lifetime cumulative ecstasy use as low as 10 tablets.   
  While the present meta-analysis is an improvement over the previously conducted meta-
analysis, there exist some limitations to conclusions based on the present study.  Heterogeneity 
existed in the aggregate effect size estimates.  Investigation of potential moderators that could 
account for the heterogeneity was limited by the amount of information reported in the primary 
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studies.  A number of strategies were used to reduce the chance of committing a Type I error.  In 
so doing, the effect size estimate might have become attenuated.   Conversely, as only published 
studies were used in the meta-analysis, the effect size might be overestimated.  The effect size 
may also have been influenced by unmeasured exogenous variables.  Finally, lack of random 
assignment to conditions may have created group selection bias.  Discussion of the limitations 
follows. 
Heterogeneity statistics revealed a significant amount of variability in the effect sizes 
from the included primary studies.  Inspection of the Forrest plots for main and sub-analyses 
revealed that much of the variability was in the magnitude of the effect sizes, as opposed to the 
direction of the effect sizes.  If the variance in the effect sizes was due to participant 
characteristics, then the true population effect will be different for different studies.  If the 
variance was due to study methodology, then there may not be differences in true effect sizes.  
The differences may be due to bias (The Cochrane Collaboration, 2005).  Sensitivity analyses 
were conducted to test if the effect would be different if more stringent exclusion criteria were 
used.  The majority of the sensitivity analyses are described earlier in this paper. 
Meta-regressions were also computed to see if the variance in effect sizes was associated 
with amount of ecstasy use or by duration of abstinence before testing. A limitation of testing the 
influence of possible moderator variables is that moderator variables in studies tend to be 
correlated and confounded with one another, making it difficult to disentangle meaningful 
relationships from spurious findings.  The observational nature of meta-analysis, most 
problematic due to lack of random assignment by the meta-analyst of moderating variables to 
different primary studies, limits the certainty of conclusions (Lipsey, 2003).   Another difficulty 
is that moderating variables tend to not be adequately reported in primary studies, as is the case 
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in the many of the studies included in the present analysis (see Table 2).  The more separate tests 
of the influence of potential moderators, the greater the chance of making a Type I error.  This 
issue can sometimes be addressed by conducting a multivariate meta-regression (The Cochrane 
Collaboration, 2005).  In the present study, multivariate moderator analysis was not tenable, due 
to uneven reporting of moderator information across the primary studies.   This is a common 
difficulty in meta-analysis (Lipsey, 2003), because the meta-analyst does not have control over 
how the primary studies are conducted or reported.  The increased chance of Type I error was 
averted by the use of a Bonferroni adjustment.  Bonferroni adjustments can, however, increase 
the chance of a Type II error (Sankoh et al., 1997).   Despite the increased chance of a Type II 
error, frequency of ecstasy use per month emerged as a moderating variable.   
A number of other strategies were used to reduce the chance of Type I error in the meta-
analysis. For example, the present procedure took the conservative approach of averaging the 
dependent outcomes (Rosenthal & DiMatteo, 2001).  In interpretation, it should be remembered 
that the effect size is likely attenuated, however, the risk of Type I error is low.  It may be useful 
in the future to use Rosenthal and Rubin’s (1986) method of combining stochastically dependent 
outcomes and compare the results to the present analysis.  The less conservative method of 
aggregation might result in a somewhat higher effect size estimate.  However, without the 
original data, it would be difficult to discern which effect size estimate is a better parameter 
estimate.  
In addition to decisions about how to aggregate the data from the included primary 
studies, search strategy decisions may have influenced the aggregate effect size estimate.  Pooled 
effect sizes can differ depending on what studies are included or excluded from the aggregation.  
Sensitivity analyses were conducted to investigate if the effect size was excessively influenced 
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by the results of one included study.   Results of sensitivity analyses suggest that the overall 
effect size for combined cognitive domains remained relatively stable when any one study was 
removed.  Sub-analyses for individual cognitive domains were similarly stable when one study 
was removed, with a few exceptions (see Tables 10-19). 
Despite an extensive search, it is possible that some published studies were not found.  
However, there is no reason to believe that the retrieved studies are not representative of the 
population of studies published in peer reviewed journals. Inspection of the funnel plot suggested 
that publication bias against non-significant results in small studies may have inflated the 
aggregate effect size.  Therefore, Rosenthal’s (1979) fail safe N was computed.  The fail safe N 
was substantially large and suggests that readers can be confident that a relationship exists 
between ecstasy use and cognitive performance.  For every study included in the meta-analysis, 
approximately 23 studies with an effect size equal to zero would need to exist in order to 
conclude that there was no statistically significant relationship between ecstasy use and cognitive 
performance. 
There are some limitations of the fail safe N that should be noted, however.  The fail safe 
N provides as estimate of the confidence that readers can have in the assertion that the effect size 
is not zero.  It does not provide an estimate of the degree to which the effect size would remain 
clinically significant if all unpublished studies were included in the analysis.  Another limitation 
is that the fail safe N assumes that the unpublished studies have an effect size equal to zero.  It 
may be that some of the unpublished studies have an effect size that is in the opposite direction, 
with ecstasy users performing better on cognitive measures than ecstasy naïve controls.  If that is 
the case, the fail safe N overestimates the number of studies that would be needed to bring the p-
value above .05 (Begg, 1994).  However, it should be noted that there may be a number of 
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unpublished, small studies in which the effect size was greater than zero, but not sufficiently 
greater to be statistically significant.   If that is the case, the fail safe N underestimates the 
number of studies that would be needed to bring the p-value above .05.   Readers should 
recognize that the fail safe N is an estimate.   
The results of the present meta-analysis could be said to be a reasonable estimate of the 
relationship between recreational ecstasy use and cognitive performance as has been measured in 
the extant literature. Statistical covariation, however, is not itself a strong argument for a causal 
relationship between ecstasy use and cognitive performance.  In the absence of randomized 
controlled trials, it is difficult to say the extent to which the results of the present meta-analysis 
approximate the true effect size for the neurocognitive consequences of ecstasy use.  A meta-
analysis comparing meta-analyses of randomized controlled trials versus meta-analyses of 
nonrandomized studies found little difference in the resultant overall effect size estimates 
(Lipsey & Wilson, 1993).  Another meta-analysis, however, found that the degree to which the 
effect size estimates differ is dependent on the quality of the nonrandomized studies (Heinsman 
& Shadish, 1996).   A number of methodological quality-related variables were identified in the 
present meta-analysis.  Due to the small number of primary studies that could be included in 
each cell, many methodological variables were not tested as potential moderators.  However, 
sensitivity analyses suggested that these variables could affect the magnitude of the aggregate 
effect size, but did not appear to influence the direction.  Even when studies used in meta-
analysis are randomized controlled trials, meta-analysis is an observational study design, because 
the meta-analyst is not randomly assigning studies to different levels of independent variables.  
As with any observational study, the certainty of conclusions derived from meta-analysis is 
limited by the possibility of unmeasured, exogenous variables (Lipsey, 2003).  
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Ambiguous temporal precedence is another obvious threat to establishing a causal 
relationship using observational studies.  It may be that premorbid impaired cognitive 
functioning exists in people who are more likely to use substances and that cognitive impairment 
hampers the decision-making process, leading people to select an immediately rewarding 
experience without consideration of possible negative consequences.  It is also possible that there 
is a reciprocal causal relationship between cognitive processes and substance use.  More than 
half of the included primary studies balanced the ecstasy use group and ecstasy naïve controls on 
general intelligence measures thought to be less likely to be impacted by lesions (see Table 4).  
Still, cognitive processes that have been associated with impulsivity and sensation-seeking have 
been found to be impacted by serotonergic dysfunction (Lezak, 1995) and trait impulsivity 
predicts escalation in drug use in rats (Robbins, 2005).  Even though participants may be 
balanced on measures not usually impacted by lesions, their pre-morbid functioning within the 
cognitive domains hypothesized to be impaired by ecstasy use may be worse than that of 
controls.  Prospective, longitudinal studies that measure serotonin-related cognitive processes 
before participants begin using ecstasy might help to disentangle the potential confounds.  
A FDA-approved, Phase II, randomized double-blind placebo-controlled pilot study of 
MDMA is currently being conducted.  The researchers are testing MDMA as a possible adjunct 
to psychotherapy in participants with posttraumatic stress disorder. Cognitive testing is being 
conducted before and after administration of MDMA (Mithoefer, 2003). The sample has limited 
generalizability and it is unlikely that the sample size for the clinical trial will be sufficient for 
the size of the effect of MDMA on cognitive performance to be statistically significant.  
Furthermore, the amount of MDMA provided to participants might not be large enough to 
produce a measurable effect, particularly considering the moderating relationship found in the 
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present meta-analysis between frequency of ecstasy use per month and effect size. Still, it is 
hoped that the researchers will conduct follow-up tests of the possible long-term cognitive 
sequelae of MDMA use.   
The moderate magnitude of the effect size found in the present meta-analysis and the 
consistency of the direction of the effect across a variety of samples is enough to caution 
researchers conducting studies on the therapeutic value to pay special attention to the margin of 
safety from a cognitive standpoint.   In addition, the present meta-analysis suggests that 
researchers conducting clinical trials of the safety of the use of MDMA should focus part of their 
assessment on measures of verbal memory.  Measures of verbal memory produced the largest 
effect sizes that continued to be statistically significant during the one study removed sensitivity 
analyses.  It is possible that measures of verbal memory would be the most sensitive to potential 
MDMA-related lesions.  However, given the results and the limitations of the present meta-
analysis, other measures of cognitive performance should also be included so as not to spuriously 
conclude that ecstasy does not cause long term cognitive impairment. 
Finally, results of this meta-analysis may be used to help educate people who may be 
considering recreational ecstasy use.  It is not recommended that the public be told that their 
cognitive performance will decrease by one-half a standard deviation if they consume ecstasy.  It 
is, however, appropriate to report that there exists within the extant published empirical literature 
a moderate relationship between relatively impaired cognitive performance and recreational 
ecstasy use. The relationship is strongest for verbal memory, but small to moderate relationships 
have also been found in nonverbal memory, reaction time, fluency, attention, and executive 
functioning.  Findings suggest that more frequent ecstasy use is associated with greater cognitive 
impairment, cognitive impairment can occur after relatively low amounts of total lifetime 
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cumulative use, and recovery of functioning does not appear to occur within one year post 
cessation.  
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Table 1: Sample size for each primary study 
 
Study Ecstasy n Control n 
Back-Madruga, et al., 2003 22 28 
Bhattachary & Powell, 2001 16 20 
Bond, et al., 2004 32 32 
Croft, et al., 2001 11 31 
Curran & Verheyden, 2003 32 32 
Daumann, et al., 2003 11 11 
Daumann, et al., 2004 13 13 
Fisk, et al., 2004 44 59 
Fox, et al., 2002 20 20 
Fox, Parrott, et al., 2001 11 20 
Gouzoulis-Mayfrank, et al., 2000 28 28 
Gouzoulis-Mayfrank, et al., 2003 30 30 
Halpern, et al., 2004 23 16 
Hanson & Luciana, 2004 26 26 
Heffernan, et al., 2001 study 2 30 37 
Jacobsen, et al., 2004 6 6 
McCann, et al., 1999 22 23 
McCardle, et al., 2004 17 15 
Montgomery, et al., 2005 22 26 
Morgan, 1998 study 1 16 12 
Morgan, 1998 study 2, 1999 25 20 
Parrott, et al., 1998 10 10 
Reneman, et al., 2000 5 9 
Reneman, Majoie, et al., 2001 8 7 
Reneman, Lavalaye, et al., 2001 16 13 
Rodgers, 2000 15 15 
Simon & Mattick, 2002 40 37 
Verkes, et al., 2001 21 20 
von Geusau, et al., 2004 men 17 12 
von Geusau, et al., 2004 women 9 21 
Wareing, et al., 2000 10 10 
Wareing, et al., 2005 12 31 
Wareing, Fisk, et al., 2004 17 31 
Wareing, Murphy, et al., 2004 10 18 
Yip & Lee, 2005 100 100 
Zakzanis, et al., 2002 24 30 
Zakzanis, et al., 2003 15 17 
Total 786 886 
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Table 2: Summary of ecstasy use for groups of ecstasy users included in the meta-analysis from 
each study. 
 


















Back-Madruga, et al., 2003 1  74.6 6.3 
Bhattachary & Powell, 2001 30    
Bond, et al., 2004 365 7 1105.85 3.5 
Croft, et al., 2001 7  41.9  
Curran & Verheyden, 2003 365 6.95  3.49 
Daumann, et al., 2003 7 2.78 258.18 4.43 
Daumann, et al., 2004 7 2.31 324.54 2.69 
Fisk, et al., 2004 7 1.76 343.38 3.52 
Fox, et al., 2002 14  172 4.33 
Fox, Parrott, et al., 2001 14  918.2 5.38 
Gouzoulis-Mayfrank, et al., 2000 7 3.5 93.4 2.25 
Gouzoulis-Mayfrank, et al., 2003 7 4.5 503.2 3.41 
Halpern, et al., 2004 10    
Hanson & Luciana, 2004 7 2.3 64.9 2.25 
Heffernan, et al., 2001 study 2 1 5.6   
Jacobsen, et al., 2004   10  
McCann, et al., 1999 21 5.72 215  
McCardle, et al., 2004 7   2.2 
Montgomery, et al., 2005 7 1.88 303.3 3.17 
Morgan, 1998 study 1 3 2.94 35.6 2.12 
Morgan, 1998 study 2, 1999 3 4.36 49.6 4.12 
Parrott, et al., 1998     
Reneman, et al., 2000 60  218  
Reneman, Majoie, et al., 2001 7  902 6.6 
Reneman, Lavalaye, et al., 2001 365  268 4.6 
Rodgers, 2000 60  20  
Simon & Mattick, 2002 1 2.4 258 3.83 
Verkes, et al., 2001 7  741 4.5 
von Geusau, et al., 2004 men 14 1.96 53.82 2.28 
von Geusau, et al., 2004 women 14 1.44 38.78 2.24 
Wareing, et al., 2000 180 8.05  3.9 
Wareing, et al., 2005 180  433  
Wareing, Fisk, et al., 2004 180  385 3.79 
Wareing, Murphy, et al., 2004 180  469.2 4.4 
Yip & Lee, 2005 1 14.8 35.84 0.2 
Zakzanis, et al., 2002 14 1.7 22.3 14.7 
Zakzanis, et al., 2003 14 2.4 19 1.53 
 
Blank cells indicate that there was no information in reference to moderator included in the study manuscript. 
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Table 3: Other substance use characteristics of ecstasy use group and control group. 









Back-Madruga, et al., 2003     
Bhattachary & Powell, 2001 non-drug users E>C y y 
Bond, et al., 2004 mixed y y  
Croft, et al., 2001 non-drug users    
Curran & Verheyden, 2003 marijuana  y y E>C 
Daumann, et al., 2003 non-drug users E>C  E>C 
Daumann, et al., 2004 marijuana E>C  E>C 
Fisk, et al., 2004 mixed E>C E>C  
Fox, et al., 2002 polydrug users y y E>C 
Fox, Parrott, et al., 2001 mixed E>C y E>C 
Gouzoulis-Mayfrank, et al., 2000 marijuana y   
Gouzoulis-Mayfrank, et al., 2003 marijuana E>C  E>C 
Halpern, et al., 2004 mixed E>C E>C  
Hanson & Luciana, 2004     
Heffernan, et al., 2001 study 2 mixed    
Jacobsen, et al., 2004 mixed y y y 
McCann, et al., 1999 mixed y  E>C 
McCardle, et al., 2004 mixed E>C E>C E>C 
Montgomery, et al., 2005 mixed E>C E>C E>C 
Morgan, 1998 study 1 polydrug users y y y 
Morgan, 1998 study 2, 1999 polydrug users y y y 
Parrott, et al., 1998     
Reneman, et al., 2000 non-drug users    
Reneman, Majoie, et al., 2001 mixed   y 
Reneman, Lavalaye, et al., 2001 mixed E>C y E>C 
Rodgers, 2000 marijuana    
Simon & Mattick, 2002 marijuana y y E>C 
Verkes, et al., 2001 mixed E>C y E>C 
von Geusau, et al., 2004 men mixed E>C  E>C 
von Geusau, et al., 2004 women mixed E>C  E>C 
Wareing, et al., 2000 non-drug users E>C  E>C 
Wareing, et al., 2005 mixed E>C C>E E>C 
Wareing, Fisk, et al., 2004 mixed    
Wareing, Murphy, et al., 2004 mixed    
Yip & Lee, 2005     
Zakzanis, et al., 2002 mixed    
Zakzanis, et al., 2003 polydrug users    
Blank cells in the description of the control group indicate that there was no information in the study manuscript in 
reference to the drug use of the control group.  “Mixed” indicates that the control group contained non-drug users and drug 
users.  Blank cells in the remainder of the columns indicate that the difference in use was not statistically tested in the 
study.  A “y” in the cell indicates that no statistical significance was found between groups.  “E>C” indicates that the 
ecstasy use group used significantly more than the control group. “C>E” indicates that the control group used significantly 
more than the ecstasy use group. 
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Table 4: Balance of demographic variables between ecstasy use group and control group. 






Back-Madruga, et al., 2003 y y y 
Bhattachary & Powell, 2001 y  y 
Bond, et al., 2004 y  E>C 
Croft, et al., 2001    
Curran & Verheyden, 2003 y  E>C 
Daumann, et al., 2003  y y 
Daumann, et al., 2004  y y 
Fisk, et al., 2004 y y y 
Fox, et al., 2002 y  y 
Fox, Parrott, et al., 2001 y C>E y 
Gouzoulis-Mayfrank, et al., 2000 C>E y y 
Gouzoulis-Mayfrank, et al., 2003 C>E y y 
Halpern, et al., 2004 y  C>E 
Hanson & Luciana, 2004 y y y 
Heffernan, et al., 2001 study 2   y 
Jacobsen, et al., 2004 y y y 
McCann, et al., 1999 y C>E C>E 
McCardle, et al., 2004 y y y 
Montgomery, et al., 2005 y y y 
Morgan, 1998 study 1 y y y 
Morgan, 1998 study 2, 1999 y y y 
Parrott, et al., 1998    
Reneman, et al., 2000  y y 
Reneman, Majoie, et al., 2001 y C>E y 
Reneman, Lavalaye, et al., 2001 y C>E y 
Rodgers, 2000    
Simon & Mattick, 2002 C>E y y 
Verkes, et al., 2001  y y 
von Geusau, et al., 2004 men  y y 
von Geusau, et al., 2004 women  y y 
Wareing, et al., 2000  y y 
Wareing, et al., 2005 y C>E y 
Wareing, Fisk, et al., 2004 y y y 
Wareing, Murphy, et al., 2004    
Yip & Lee, 2005 y y y 
Zakzanis, et al., 2002 y y y 
Zakzanis, et al., 2003 C>E y y 
 
Blank cells indicate that the difference in the demographic variable was not statistically tested in the study.  A “y” in 
the cell indicates that no statistical significance was found between groups.  “E>C” indicates that the ecstasy use 
group mean was significantly higher than the control group on that variable. “C>E” indicates that the control group 
mean was significantly higher than the ecstasy use group on that variable. 
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Table 5:  Combined estimated effect size using Hedge’s g 
 















37 -0.498 0.052 0.003 -0.600 -0.395 -9.547 0.0000 
Random 
effects 
37 -0.515 0.083 0.007 -0.678 -0.353 -6.220 0.0000 
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Table 6:  Heterogeneity statistics 
 
Estimate Q-value df (Q) P-value I2
Combined cognitive domains 84.252 36 0.000 57.271 
Cognitive domains analyzed separately     
Attention 61.932 21 0.000 66.092 
Immediate verbal memory 80.376 25 0.000 68.896 
Delayed verbal memory 273.306 17 0.000 93.780 
Immediate nonverbal memory 35.888 19 0.011 47.058 
Delayed nonverbal memory 77.765 9 0.000 88.427 
Executive functioning 15.352 12 0.223 21.835 
Fluency 22.226 9 0.008 59.507 
Reaction time 25.845 11 0.004 61.307 
Learning 4.55 7 0.714 0.000 
Control group consists of      
marijuana users 1.890 5 0.864 0.000 
non-drug users 7.013 4 0.135 42.962 
polydrug users 0.065 3 0.996 0.000 
mixed 39.813 17 0.001 57.300 
Including only studies with control 
groups balanced for alcohol, 
marijuana, and other substance use 
0.957 3 0.620 0.000 
Including only studies with control 
groups balanced for intelligence, 
education, and age 





Table 7: Aggregate effect sizes for sub-analyses by cognitive domain  
 







Attention Random 22 -0.297 0.113 -2.625 0.009 
 Fixed  -0.296 0.063 -4.726 0.000 
Immediate verbal memory Random 26 -0.634 0.112 -5.653 0.000 
 Fixed  -0.640 0.061 -10.542 0.000 
Delayed verbal memory Random 18 -0.880 0.317 -2.773 0.006 
 Fixed  -0.830 0.078 -10.621 0.000 
Immediate nonverbal memory Random 20 -0.428 0.095 -4.511 0.000 
 Fixed  -0.427 0.066 -6.501 0.000 
Delayed nonverbal memory Random 10 -0.634 0.265 -2.390 0.017 
 Fixed  -0.667 0.086 -7.729 0.000 
Executive functioning Random 13 -0.238 0.100 -2.385 0.017 
 Fixed  -0.226 0.086 -2.626 0.009 
Fluency Random 10 -0.452 0.140 -3.220 0.001 
 Fixed  -0.455 0.085 -5.342 0.000 
Reaction time Random 11 -0.492 0.178 -2.756 0.006 
 Fixed  -0.431 0.107 -4.027 0.000 
Learning Random 8 -0.151 0.112 -1.349 0.177 
 Fixed  -0.151 0.112 -1.349 0.177 
 




Table 8: Mixed effects regression (unrestricted maximum likelihood) of potential moderator 












30  0.17 30.21 30.39 -0.417 0.6768 
Frequency of 
ecstasy use per 
month 
20 -0.091 33.60 27.44 61.04 -5.797 0.0000 
Number of years 
used ecstasy 
27  3.22 25.73 28.95 1.79 0.0729 
Number of years 
used ecstasy, with 
one extreme score 
removed 






35  0.33 35.26 35.59 -0.572 0.5670 
 
Slope point estimates are included only for variables that are related to a significant amount of variance in effect 
sizes.  Bonferroni adjusted Zcritical = +/- 2.5688. 
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Table 9: Sensitivity analysis.  Aggregate effect sizes for sub-analyses of type of control group 
using random effects model 
 
 

























 mixed 18 -0.571 0.122 -4.679 0.000 
 marijuana users 6 -0.345 0.118 -2.924 0.003 
 polydrug users 4 -0.250 0.165 -1.511 0.131 
Including only 
studies with control 
groups balanced for 
alcohol, marijuana, 
and other substance 
use 
 3 -0.338 0.217 -1.558 0.119 
Including only 
studies with control 
groups balanced for 
intelligence, 
education, and age 
 11 -0.348 0.169 -2.061 0.039 
 69
 
Table 10:  Combined estimated effect size using Hedge’s g and the random effects model with 















Back-Madruga, et al., 2003 -0.536 0.083 0.007 -0.698 -0.374 -6.468 0.000 
Bhattachary & Powell, 2001 -0.494 0.082 0.007 -0.655 -0.332 -5.997 0.000 
Bond, et al., 2004 -0.527 0.085 0.007 -0.694 -0.361 -6.196 0.000 
Croft, et al., 2001 -0.515 0.085 0.007 -0.682 -0.349 -6.063 0.000 
Curran & Verheyden, 2003 -0.521 0.085 0.007 -0.687 -0.354 -6.120 0.000 
Daumann, et al., 2003 -0.525 0.084 0.007 -0.690 -0.360 -6.227 0.000 
Daumann, et al., 2004 -0.508 0.084 0.007 -0.674 -0.343 -6.021 0.000 
Fisk, et al., 2004 -0.533 0.084 0.007 -0.698 -0.369 -6.348 0.000 
Fox, et al., 2002 -0.522 0.085 0.007 -0.689 -0.356 -6.141 0.000 
Fox, Parrott, et al., 2001 -0.521 0.085 0.007 -0.687 -0.355 -6.147 0.000 
Gouzoulis-Mayfrank, et al., 2000 -0.522 0.086 0.007 -0.689 -0.354 -6.100 0.000 
Gouzoulis-Mayfrank, et al., 2003 -0.522 0.086 0.007 -0.690 -0.354 -6.098 0.000 
Halpern, et al., 2004 -0.519 0.085 0.007 -0.686 -0.352 -6.091 0.000 
Hanson & Luciana, 2004 -0.529 0.085 0.007 -0.695 -0.363 -6.245 0.000 
Heffernan, et al., 2001 study 2 -0.503 0.085 0.007 -0.669 -0.337 -5.938 0.000 
Jacobsen, et al., 2004 -0.510 0.084 0.007 -0.675 -0.346 -6.080 0.000 
McCann, et al., 1999 -0.481 0.079 0.006 -0.636 -0.326 -6.101 0.000 
McCardle, et al., 2004 -0.521 0.085 0.007 -0.687 -0.354 -6.131 0.000 
Montgomery, et al., 2005 -0.519 0.085 0.007 -0.686 -0.351 -6.072 0.000 
Morgan, 1998 study 1 -0.522 0.085 0.007 -0.688 -0.357 -6.173 0.000 
Morgan, 1998 study 2, 1999 -0.524 0.085 0.007 -0.691 -0.357 -6.163 0.000 
Parrott, et al., 1998 -0.520 0.084 0.007 -0.686 -0.355 -6.158 0.000 
Reneman, et al., 2000 -0.500 0.082 0.007 -0.661 -0.338 -6.062 0.000 
Reneman, Majoie, et al., 2001 -0.507 0.084 0.007 -0.672 -0.343 -6.050 0.000 
Reneman, Lavalaye, et al., 2001 -0.500 0.083 0.007 -0.664 -0.337 -5.992 0.000 
Rodgers, 2000 -0.522 0.085 0.007 -0.688 -0.356 -6.155 0.000 
Simon & Mattick, 2002 -0.528 0.085 0.007 -0.695 -0.361 -6.186 0.000 
Verkes, et al., 2001 -0.505 0.085 0.007 -0.671 -0.340 -5.977 0.000 
von Geusau, et al., 2004 men -0.503 0.083 0.007 -0.667 -0.340 -6.040 0.000 
von Geusau, et al., 2004 women -0.536 0.082 0.007 -0.696 -0.376 -6.556 0.000 
Wareing, et al., 2000 -0.508 0.084 0.007 -0.673 -0.343 -6.041 0.000 
Wareing, et al., 2005 -0.501 0.084 0.007 -0.666 -0.337 -5.979 0.000 
Wareing, Fisk, et al., 2004 -0.519 0.085 0.007 -0.686 -0.351 -6.078 0.000 
Wareing, Murphy, et al., 2004 -0.508 0.084 0.007 -0.673 -0.343 -6.020 0.000 
Yip & Lee, 2005 -0.466 0.074 0.005 -0.611 -0.321 -6.314 0.000 
Zakzanis, et al., 2002 -0.534 0.084 0.007 -0.698 -0.370 -6.391 0.000 
Zakzanis, et al., 2003 -0.525 0.085 0.007 -0.691 -0.359 -6.204 0.000 
Overall ES -0.515 0.083 0.007 -0.678 -0.353 -6.220 0.000 
 




Table 11: Aggregate estimated effect size for measures of attention using Hedge’s g and the 













Back-Madruga, et al., 2003 -0.318 0.117 0.014 -0.548 -0.089 -2.724 0.006 
Bond, et al., 2004 -0.303 0.120 0.014 -0.538 -0.069 -2.533 0.011 
Croft, et al., 2001 -0.277 0.116 0.014 -0.505 -0.049 -2.384 0.017 
Curran & Verheyden, 2003 -0.299 0.119 0.014 -0.532 -0.066 -2.514 0.012 
Fox, et al., 2002 -0.297 0.118 0.014 -0.529 -0.065 -2.508 0.012 
Gouzoulis-Mayfrank, et al., 2000 -0.300 0.119 0.014 -0.534 -0.066 -2.515 0.012 
Gouzoulis-Mayfrank, et al., 2003 -0.308 0.119 0.014 -0.541 -0.074 -2.583 0.010 
Halpern, et al., 2004 -0.288 0.118 0.014 -0.519 -0.057 -2.441 0.015 
Hanson & Luciana, 2004 -0.302 0.119 0.014 -0.535 -0.069 -2.537 0.011 
Jacobsen, et al., 2004 -0.295 0.116 0.013 -0.522 -0.067 -2.541 0.011 
McCann, et al., 1999 -0.223 0.072 0.005 -0.363 -0.083 -3.113 0.002 
McCardle, et al., 2004 -0.294 0.118 0.014 -0.524 -0.063 -2.495 0.013 
Morgan, 1998 study 1 -0.290 0.117 0.014 -0.520 -0.061 -2.477 0.013 
Morgan, 1998 study 2, 1999 -0.297 0.119 0.014 -0.529 -0.064 -2.504 0.012 
Parrott, et al., 1998 -0.305 0.117 0.014 -0.534 -0.077 -2.619 0.009 
Rodgers, 2000 -0.306 0.117 0.014 -0.536 -0.076 -2.607 0.009 
Simon & Mattick, 2002 -0.306 0.120 0.014 -0.541 -0.071 -2.549 0.011 
von Geusau, et al., 2004 men -0.312 0.117 0.014 -0.541 -0.084 -2.676 0.007 
von Geusau, et al., 2004 women -0.347 0.103 0.011 -0.548 -0.145 -3.374 0.001 
Wareing, et al., 2000 -0.282 0.116 0.013 -0.509 -0.055 -2.435 0.015 
Yip & Lee, 2005 -0.285 0.123 0.015 -0.527 -0.044 -2.315 0.021 
Zakzanis, et al., 2002 -0.316 0.118 0.014 -0.546 -0.085 -2.683 0.007 
Overall ES -0.297 0.113 0.013 -0.518 -0.075 -2.625 0.009 
 
Information listed on row of named study represents the aggregate estimate with that study removed. 
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Table 12: Aggregate estimated effect size for measures of immediate verbal memory using 













Back-Madruga, et al., 2003 -0.679 0.106 0.011 -0.887 -0.472 -6.422 0.000 
Bhattachary & Powell, 2001 -0.601 0.112 0.013 -0.820 -0.382 -5.374 0.000 
Croft, et al., 2001 -0.636 0.116 0.013 -0.863 -0.408 -5.470 0.000 
Curran & Verheyden, 2003 -0.642 0.116 0.013 -0.869 -0.415 -5.538 0.000 
Daumann, et al., 2003 -0.654 0.114 0.013 -0.878 -0.431 -5.744 0.000 
Fisk, et al., 2004 -0.635 0.119 0.014 -0.869 -0.401 -5.321 0.000 
Fox, Parrott, et al., 2001 -0.650 0.115 0.013 -0.875 -0.425 -5.657 0.000 
Gouzoulis-Mayfrank, et al., 2000 -0.646 0.117 0.014 -0.875 -0.417 -5.529 0.000 
Gouzoulis-Mayfrank, et al., 2003 -0.648 0.117 0.014 -0.877 -0.419 -5.550 0.000 
Halpern, et al., 2004 -0.646 0.116 0.013 -0.873 -0.418 -5.567 0.000 
Hanson & Luciana, 2004 -0.654 0.115 0.013 -0.880 -0.428 -5.670 0.000 
McCardle, et al., 2004 -0.642 0.116 0.013 -0.870 -0.415 -5.542 0.000 
Montgomery, et al., 2005 -0.630 0.117 0.014 -0.860 -0.401 -5.394 0.000 
Morgan, 1998 study 2, 1999 -0.621 0.116 0.013 -0.849 -0.394 -5.349 0.000 
Parrott, et al., 1998 -0.619 0.114 0.013 -0.843 -0.395 -5.410 0.000 
Reneman, Majoie, et al., 2001 -0.626 0.115 0.013 -0.851 -0.401 -5.460 0.000 
Reneman, Lavalaye, et al., 2001 -0.616 0.115 0.013 -0.841 -0.392 -5.375 0.000 
Rodgers, 2000 -0.643 0.116 0.013 -0.870 -0.416 -5.557 0.000 
Simon & Mattick, 2002 -0.645 0.118 0.014 -0.876 -0.414 -5.473 0.000 
Verkes, et al., 2001 -0.623 0.116 0.013 -0.851 -0.396 -5.368 0.000 
von Geusau, et al., 2004 men -0.584 0.106 0.011 -0.791 -0.376 -5.519 0.000 
von Geusau, et al., 2004 women -0.656 0.114 0.013 -0.879 -0.433 -5.764 0.000 
Wareing, et al., 2005 -0.610 0.114 0.013 -0.833 -0.387 -5.353 0.000 
Wareing, Fisk, et al., 2004 -0.643 0.116 0.014 -0.871 -0.414 -5.517 0.000 
Yip & Lee, 2005 -0.571 0.097 0.009 -0.762 -0.380 -5.867 0.000 
Zakzanis, et al., 2003 -0.646 0.116 0.013 -0.873 -0.419 -5.586 0.000 
Overall ES -0.634 0.112 0.013 -0.853 -0.414 -5.653 0.000 
 




Table 13: Aggregate estimated effect size for measures of delayed verbal memory using Hedge’s 













Back-Madruga, et al., 2003 -0.954 0.329 0.108 -1.599 -0.309 -2.900 0.004 
Bhattachary & Powell, 2001 -0.811 0.328 0.107 -1.453 -0.169 -2.477 0.013 
Croft, et al., 2001 -0.907 0.335 0.112 -1.563 -0.250 -2.705 0.007 
Curran & Verheyden, 2003 -0.897 0.335 0.113 -1.554 -0.239 -2.673 0.008 
Fox, Parrott, et al., 2001 -0.951 0.329 0.108 -1.595 -0.307 -2.893 0.004 
Gouzoulis-Mayfrank, et al., 2000 -0.908 0.341 0.116 -1.576 -0.240 -2.664 0.008 
Gouzoulis-Mayfrank, et al., 2003 -0.888 0.342 0.117 -1.560 -0.217 -2.594 0.009 
Halpern, et al., 2004 -0.914 0.336 0.113 -1.572 -0.255 -2.720 0.007 
McCardle, et al., 2004 -0.910 0.335 0.112 -1.566 -0.253 -2.716 0.007 
Morgan, 1998 study 2, 1999 -0.884 0.339 0.115 -1.549 -0.219 -2.606 0.009 
Parrott, et al., 1998 -0.865 0.331 0.110 -1.515 -0.216 -2.611 0.009 
Reneman, et al., 2000 -0.843 0.328 0.108 -1.486 -0.200 -2.571 0.010 
Reneman, Majoie, et al., 2001 -0.870 0.330 0.109 -1.518 -0.223 -2.636 0.008 
Reneman, Lavalaye, et al., 2001 -0.866 0.334 0.111 -1.520 -0.212 -2.595 0.009 
Rodgers, 2000 -0.892 0.335 0.112 -1.548 -0.236 -2.666 0.008 
Simon & Mattick, 2002 -0.917 0.344 0.118 -1.590 -0.243 -2.668 0.008 
Yip & Lee, 2005 -0.575 0.141 0.020 -0.851 -0.299 -4.089 0.000 
Zakzanis, et al., 2003 -0.945 0.330 0.109 -1.592 -0.298 -2.862 0.004 
Overall ES -0.880 0.317 0.101 -1.502 -0.258 -2.773 0.006 
 




Table 14: Aggregate estimated effect size for measures of immediate nonverbal memory using 













Back-Madruga, et al., 2003 -0.451 0.098 0.010 -0.643 -0.259 -4.598 0.000 
Croft, et al., 2001 -0.437 0.099 0.010 -0.632 -0.243 -4.412 0.000 
Daumann, et al., 2004 -0.413 0.097 0.009 -0.604 -0.222 -4.234 0.000 
Fox, et al., 2002 -0.430 0.100 0.010 -0.626 -0.234 -4.306 0.000 
Fox, Parrott, et al., 2001 -0.398 0.094 0.009 -0.582 -0.214 -4.240 0.000 
Gouzoulis-Mayfrank, et al., 2000 -0.423 0.101 0.010 -0.620 -0.225 -4.201 0.000 
Gouzoulis-Mayfrank, et al., 2003 -0.423 0.101 0.010 -0.620 -0.225 -4.193 0.000 
Halpern, et al., 2004 -0.425 0.100 0.010 -0.621 -0.230 -4.264 0.000 
Hanson & Luciana, 2004 -0.453 0.098 0.010 -0.644 -0.262 -4.645 0.000 
McCann, et al., 1999 -0.456 0.096 0.009 -0.643 -0.268 -4.768 0.000 
Morgan, 1998 study 1 -0.442 0.098 0.010 -0.634 -0.249 -4.499 0.000 
Rodgers, 2000 -0.448 0.097 0.009 -0.638 -0.257 -4.605 0.000 
Simon & Mattick, 2002 -0.462 0.095 0.009 -0.649 -0.275 -4.844 0.000 
Verkes, et al., 2001 -0.401 0.096 0.009 -0.589 -0.213 -4.176 0.000 
von Geusau, et al., 2004 men -0.385 0.087 0.008 -0.554 -0.215 -4.437 0.000 
von Geusau, et al., 2004 women -0.446 0.097 0.009 -0.637 -0.255 -4.585 0.000 
Wareing, et al., 2005 -0.405 0.097 0.009 -0.595 -0.216 -4.194 0.000 
Wareing, Murphy, et al., 2004 -0.412 0.097 0.009 -0.603 -0.221 -4.236 0.000 
Yip & Lee, 2005 -0.413 0.103 0.011 -0.615 -0.211 -4.011 0.000 
Zakzanis, et al., 2003 -0.449 0.097 0.009 -0.639 -0.258 -4.611 0.000 
Overall ES -0.428 0.095 0.009 -0.614 -0.242 -4.511 0.000 
 




Table 15: Aggregate estimated effect size for measures of delayed nonverbal memory using 













Back-Madruga, et al., 2003 -0.691 0.291 0.085 -1.261 -0.121 -2.375 0.018 
Bhattachary & Powell, 2001 -0.702 0.285 0.081 -1.261 -0.142 -2.459 0.014 
Croft, et al., 2001 -0.694 0.286 0.082 -1.254 -0.133 -2.424 0.015 
Gouzoulis-Mayfrank, et al., 2003 -0.634 0.300 0.090 -1.222 -0.045 -2.110 0.035 
Halpern, et al., 2004 -0.669 0.291 0.085 -1.240 -0.098 -2.297 0.022 
McCann, et al., 1999 -0.372 0.202 0.041 -0.769 0.024 -1.839 0.066 
Rodgers, 2000 -0.654 0.290 0.084 -1.221 -0.086 -2.258 0.024 
Simon & Mattick, 2002 -0.703 0.291 0.085 -1.274 -0.132 -2.412 0.016 
Yip & Lee, 2005 -0.542 0.269 0.073 -1.070 -0.014 -2.012 0.044 
Zakzanis, et al., 2003 -0.711 0.282 0.080 -1.265 -0.158 -2.521 0.012 
Overall ES -0.634 0.265 0.070 -1.154 -0.114 -2.390 0.017 
 




Table 16: Aggregate estimated effect size for measures of executive functioning using Hedge’s g 













Back-Madruga, et al., 2003 -0.272 0.104 0.011 -0.476 -0.068 -2.608 0.009 
Fisk, et al., 2004 -0.277 0.109 0.012 -0.490 -0.063 -2.543 0.011 
Fox, Parrott, et al., 2001 -0.235 0.107 0.012 -0.446 -0.025 -2.192 0.028 
Gouzoulis-Mayfrank, et al., 2000 -0.174 0.094 0.009 -0.358 0.010 -1.857 0.063 
Gouzoulis-Mayfrank, et al., 2003 -0.242 0.111 0.012 -0.460 -0.024 -2.177 0.030 
Halpern, et al., 2004 -0.215 0.105 0.011 -0.421 -0.009 -2.049 0.040 
Montgomery, et al., 2005 -0.240 0.110 0.012 -0.455 -0.025 -2.189 0.029 
Morgan, 1998 study 1 -0.244 0.108 0.012 -0.455 -0.033 -2.267 0.023 
Morgan, 1998 study 2, 1999 -0.269 0.104 0.011 -0.474 -0.064 -2.576 0.010 
von Geusau, et al., 2004 men -0.227 0.103 0.011 -0.430 -0.025 -2.198 0.028 
von Geusau, et al., 2004 women -0.265 0.091 0.008 -0.443 -0.086 -2.911 0.004 
Wareing, et al., 2000 -0.203 0.095 0.009 -0.390 -0.017 -2.135 0.033 
Zakzanis, et al., 2003 -0.218 0.105 0.011 -0.423 -0.012 -2.078 0.038 
Overall ES -0.238 0.100 0.010 -0.433 -0.042 -2.385 0.017 
 




Table 17: Aggregate estimated effect size for measures of fluency using Hedge’s g and the 













Back-Madruga, et al., 2003 -0.541 0.119 0.014 -0.775 -0.308 -4.541 0.000 
Bhattachary & Powell, 2001 -0.370 0.122 0.015 -0.608 -0.131 -3.040 0.002 
Croft, et al., 2001 -0.426 0.151 0.023 -0.723 -0.130 -2.823 0.005 
Curran & Verheyden, 2003 -0.486 0.150 0.022 -0.779 -0.193 -3.248 0.001 
Fox, et al., 2002 -0.455 0.155 0.024 -0.760 -0.151 -2.936 0.003 
Gouzoulis-Mayfrank, et al., 2000 -0.466 0.157 0.025 -0.775 -0.158 -2.963 0.003 
Halpern, et al., 2004 -0.460 0.155 0.024 -0.763 -0.158 -2.980 0.003 
Hanson & Luciana, 2004 -0.485 0.153 0.024 -0.786 -0.184 -3.161 0.002 
Heffernan, et al., 2001 study 2 -0.400 0.148 0.022 -0.690 -0.109 -2.697 0.007 
Yip & Lee, 2005 -0.439 0.168 0.028 -0.768 -0.110 -2.615 0.009 
Overall ES -0.452 0.140 0.020 -0.727 -0.177 -3.220 0.001 
 




Table 18: Aggregate estimated effect size for measures of reaction time using Hedge’s g and the 













Daumann, et al., 2003 -0.446 0.111 0.012 -0.663 -0.229 -4.025 0.000 
Fox, et al., 2002 -0.441 0.114 0.013 -0.665 -0.218 -3.874 0.000 
Fox, Parrott, et al., 2001 -0.430 0.112 0.013 -0.649 -0.211 -3.845 0.000 
Gouzoulis-Mayfrank, et al., 2000 -0.450 0.117 0.014 -0.679 -0.221 -3.852 0.000 
Gouzoulis-Mayfrank, et al., 2003 -0.454 0.118 0.014 -0.684 -0.223 -3.849 0.000 
Jacobsen, et al., 2004 -0.402 0.109 0.012 -0.615 -0.189 -3.695 0.000 
Parrott, et al., 1998 -0.468 0.111 0.012 -0.685 -0.252 -4.236 0.000 
Rodgers, 2000 -0.456 0.112 0.013 -0.676 -0.236 -4.067 0.000 
Verkes, et al., 2001 -0.394 0.114 0.013 -0.617 -0.171 -3.463 0.001 
von Geusau, et al., 2004 men -0.338 0.109 0.012 -0.552 -0.124 -3.091 0.002 
von Geusau, et al., 2004 women -0.472 0.111 0.012 -0.689 -0.255 -4.260 0.000 
Overall ES -0.431 0.107 0.011 -0.641 -0.221 -4.027 0.000 
 




Table 19: Aggregate estimated effect size for measures of learning using Hedge’s g and the 













Back-Madruga, et al., 2003 -0.243 0.122 0.015 -0.482 -0.004 -1.989 0.047 
Croft, et al., 2001 -0.110 0.118 0.014 -0.342 0.122 -0.928 0.353 
Curran & Verheyden, 2003 -0.138 0.118 0.014 -0.371 0.094 -1.169 0.242 
Fox, et al., 2002 -0.154 0.120 0.014 -0.390 0.081 -1.284 0.199 
Gouzoulis-Mayfrank, et al., 2000 -0.148 0.123 0.015 -0.390 0.094 -1.196 0.232 
Halpern, et al., 2004 -0.153 0.120 0.014 -0.388 0.082 -1.278 0.201 
McCardle, et al., 2004 -0.138 0.118 0.014 -0.370 0.094 -1.167 0.243 
Zakzanis, et al., 2003 -0.131 0.118 0.014 -0.363 0.101 -1.107 0.268 
Overall ES -0.151 0.112 0.013 -0.371 0.068 -1.349 0.177 
 








Figure 1:  Forrest plot of primary study effect sizes for combined cognitive domains. 
 
Model Study name Outcome Hedges's g and 95%  CI
Back-Madruga, et al., 2003 Combined
Bhattachary & Powell, 2001 Combined
Bond, et al., 2004 processing speed
Croft, et al., 2001 Combined
Curran & Verheyden, 2003 Combined
Daumann, et al., 2003 Combined
Daumann, et al., 2004 LGT-3 Logos immediate recall
Fisk, et al., 2004 Combined
Fox, et al., 2002 Combined
Fox, Parrott, et al., 2001 Combined
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Halpern, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
Heffernan, et al., 2001 study 2 Combined
Jacobsen, et al., 2004 Combined
McCann, et al., 1999 Combined
McCardle, et al., 2004 Combined
Montgomery, et al., 2005 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
Parrott, et al., 1998 Combined
Reneman, et al., 2000 Rey Auditory Verbal Learning Test delayed recall
Reneman, Lavalaye, et al., 2001 Combined
Reneman, Majoie, et al., 2001 Combined
Rodgers, 2000 Combined
Simon & Mattick, 2002 Combined
Verkes, et al., 2001 Combined
von Geusau, et al., 2004 men Combined
von Geusau, et al., 2004 women Combined
Wareing, et al., 2000 Combined
Wareing, et al., 2005 Combined
Wareing, Fisk, et al., 2004 Combined
Wareing, Murphy, et al., 2004 Combined
Yip & Lee, 2005 Combined
Zakzanis, et al., 2002 Combined
Zakzanis, et al., 2003 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 2: Funnel plot for the aggregate effect size for combined cognitive domains under the 
random effects model. 
 














Funnel Plot of Standard Error by Hedges's g
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Figure 3: Forrest plot for measures of attention. 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Bond, et al., 2004 processing speed
Croft, et al., 2001 Combined
Curran & Verheyden, 2003 Combined
Fox, et al., 2002 Combined
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Halpern, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
Jacobsen, et al., 2004 Combined
McCann, et al., 1999 Combined
McCardle, et al., 2004 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
Parrott, et al., 1998 Combined
Rodgers, 2000 WMS-III mental control
Simon & Mattick, 2002 WMS-III working
von Geusau, et al., 2004 men Combined
von Geusau, et al., 2004 women Combined
Wareing, et al., 2000 Combined
Yip & Lee, 2005 Combined
Zakzanis, et al., 2002 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 4: Forrest plot for measures of immediate verbal memory 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Bhattachary & Powell, 2001 Combined
Croft, et al., 2001 Combined
Curran & Verheyden, 2003 Combined
Daumann, et al., 2003 Combined
Fisk, et al., 2004 Computation Span
Fox, Parrott, et al., 2001 Combined
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Halpern, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
McCardle, et al., 2004 Combined
Montgomery, et al., 2005 Combined
Morgan, 1998 study 2, 1999 Rivermead Behavioral Memory Test immediate prose recall
Parrott, et al., 1998 immediate word recall
Reneman, Lavalaye, et al., 2001 Rey Auditory Verbal Learning Test immediate recall
Reneman, Majoie, et al., 2001 Rey Auditory Verbal Learning Test immediate recall
Rodgers, 2000 Combined
Simon & Mattick, 2002 WMS-III auditory immediate
Verkes, et al., 2001 Combined
von Geusau, et al., 2004 men Mental Counters % correct
von Geusau, et al., 2004 women Mental Counters % correct
Wareing, et al., 2005 computation span
Wareing, Fisk, et al., 2004 Combined
Yip & Lee, 2005 Combined
Zakzanis, et al., 2003 Rivermead Behavioral Memory Test immediate prose recall
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 5: Forrest plot for measures of delayed verbal memory 
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Bhattachary & Powell, 2001 prose recall delayed
Croft, et al., 2001 Coughlan list B
Curran & Verheyden, 2003 Combined
Fox, Parrott, et al., 2001 delayed prose recall
Gouzoulis-Mayfrank, et al., 2000 VLMT delayed recall
Gouzoulis-Mayfrank, et al., 2003 LGT-3 German-Turkish delayed recall
Halpern, et al., 2004 Combined
McCardle, et al., 2004 Rey Auditory Verbal Learning Test trial  8
Morgan, 1998 study 2, 1999 Rivermead Behavioral Memory Test delayed prose recall
Parrott, et al., 1998 delayed word recall
Reneman, et al., 2000 Rey Auditory Verbal Learning Test delayed recall
Reneman, Lavalaye, et al., 2001 Rey Auditory Verbal Learning Test delayed recall
Reneman, Majoie, et al., 2001 Rey Auditory Verbal Learning Test delayed recall
Rodgers, 2000 Combined
Simon & Mattick, 2002 Combined
Yip & Lee, 2005 Combined
Zakzanis, et al., 2003 Rivermead Behavioral Memory Test delayed prose recall
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 6: Forrest plot for measures of immediate nonverbal memory  
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Croft, et al., 2001 Coughlan design 6
Daumann, et al., 2004 LGT-3 Logos immediate recall
Fox, et al., 2002 Combined
Fox, Parrott, et al., 2001 spatial recall
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Halpern, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
McCann, et al., 1999 Combined
Morgan, 1998 study 1 Combined
Rodgers, 2000 Combined
Simon & Mattick, 2002 WMS-III visual immediate
Verkes, et al., 2001 Combined
von Geusau, et al., 2004 men Tic Tac Toe % correct
von Geusau, et al., 2004 women Tic Tac Toe % correct
Wareing, et al., 2005 Combined
Wareing, Murphy, et al., 2004 Combined
Yip & Lee, 2005 Aggie Figures Learning Test immediate
Zakzanis, et al., 2003 Rivermead Behavioral Memory Test immediate route
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 7:  Forrest plot for measures of delayed nonverbal memory 
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Bhattachary & Powell, 2001 Rey-Osterreith recall
Croft, et al., 2001 Coughlan design B
Gouzoulis-Mayfrank, et al., 2003 Combined
Halpern, et al., 2004 Combined
McCann, et al., 1999 delayed code substitution with no key
Rodgers, 2000 Combined
Simon & Mattick, 2002 WMS-III visual delayed
Yip & Lee, 2005 Combined
Zakzanis, et al., 2003 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00




Figure 8: Forrest plot for measures of executive functioning. 
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Fisk, et al., 2004 Combined
Fox, Parrott, et al., 2001 Combined
Gouzoulis-Mayfrank, et al., 2000Combined
Gouzoulis-Mayfrank, et al., 2003Combined
Halpern, et al., 2004 Combined
Montgomery, et al., 2005 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
von Geusau, et al., 2004 men Combined
von Geusau, et al., 2004 womenCombined
Wareing, et al., 2000 Combined
Zakzanis, et al., 2003 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00




Figure 9: Forrest plot for measures of fluency. 
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Bhattachary & Powell, 2001 verbal fluency
Croft, et al., 2001 Combined
Curran & Verheyden, 2003 phonemic fluency
Fox, et al., 2002 Combined
Gouzoulis-Mayfrank, et al., 2000 Combined
Halpern, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
Heffernan, et al., 2001 study 2 Combined
Yip & Lee, 2005 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 10: Forrest plot for measures of reaction time. 
 
Model Study name Outcome Hedges's g and 95% CI
Daumann, et al., 2003 Combined
Fox, et al., 2002 Combined
Fox, Parrott, et al., 2001 simple reaction time
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Jacobsen, et al., 2004 Combined
Parrott, et al., 1998 simple reaction time
Rodgers, 2000 Combined
Verkes, et al., 2001 Combined
von Geusau, et al., 2004 men Combined
von Geusau, et al., 2004 women Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00




Figure 11: Forrest plot for measures of learning. 
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Rey Auditory Verbal Learning Test trial 5
Croft, et al., 2001 Combined
Curran & Verheyden, 2003 Buschke SRT 3-1
Fox, et al., 2002 Combined
Gouzoulis-Mayfrank, et al., 2000 Combined
Halpern, et al., 2004 Combined
McCardle, et al., 2004 Combined
Zakzanis, et al., 2003 Rivermead Behavioral Memory Test 1st/2nd name
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00




Figure 12: Forrest plot of primary studies that used non-substance users as the control group.  
Cognitive domains were combined 
 
Model Study name Outcome Hedges's g and 95% CI
Bhattachary & Powell, 2001 Combined
Croft, et al., 2001 Combined
Daumann, et al., 2003 Combined
Reneman, et al., 2000 Rey Auditory Verbal Learning Test delayed recall
Wareing, et al., 2000 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 13: Forrest plot of primary studies that used a mixed group of substance users and non-
substance users as the control group.  Cognitive domains were combined. 
  
Model Study name Outcome Hedges's g and 95% CI
Bond, et al., 2004 processing speed
Fisk, et al., 2004 Combined
Fox, Parrott, et al., 2001 Combined
Halpern, et al., 2004 Combined
Heffernan, et al., 2001 study 2 Combined
Jacobsen, et al., 2004 Combined
McCann, et al., 1999 Combined
McCardle, et al., 2004 Combined
Montgomery, et al., 2005 Combined
Reneman, et al., 2001 Combined
Reneman, Lavalaye, et al., 2001 Combined
Verkes, et al., 2001 Combined
von Geusau, et al., 2004 men Combined
von Geusau, et al., 2004 women Combined
Wareing, et al., 2005 Combined
Wareing, Fisk, et al., 2004 Combined
Wareing, Murphy, et al., 2004 Combined
Zakzanis, et al., 2002 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 14: Forrest plot of primary studies that used marijuana users as the control group.  
Cognitive domains were combined 
Model Study name Outcome Hedges's g and 95% CI
Curran & Verheyden, 2003 Combined
Daumann, et al., 2004 LGT-3 Logos immediate recall
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Rodgers, 2000 Combined
Simon & Mattick, 2002 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 15: Forrest plot of primary studies that used polysubstance users as the control group.  
Cognitive domains were combined. 
 
Model Study name Outcome Hedges's g and 95% CI
Fox, et al., 2002 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
Zakzanis, et al., 2003 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00




Figure 16: Mixed effects meta-regression using unrestricted maximum likelihood to test reported 
total lifetime cumulative ecstasy use as a potential moderator. 
 






















Figure 17: Mixed effects meta-regression using unrestricted maximum likelihood to test reported 
frequency of ecstasy use per month as a potential moderator. 
 
Regression of frequency MDMA used per month on Hedges's g





















Figure 18: Mixed effects meta-regression using unrestricted maximum likelihood to test reported 
number of years participants used ecstasy as a potential moderator. 
 
 






















Figure 19: Mixed effects meta-regression using unrestricted maximum likelihood to test reported 
number of years participants used ecstasy as a potential moderator, with an extreme score 
removed. 
 























Figure 20: Mixed effects meta-regression using unrestricted maximum likelihood to test 
minimum required duration of abstinence before cognitive testing as a potential moderator. 
 
Regression of time since used MDMA on Hedges's g




















Figure 21: Forrest plot for studies in which the control group was balanced for alcohol, 
marijuana, and other substance use. 
 
Model Study name Outcome Hedges's g and 95% CI
Jacobsen, et al., 2004 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 22: Forrest plot for studies in which the control group was balanced for intelligence, 
education, and age. 
 
Model Study name Outcome Hedges's g and 95% CI
Back-Madruga, et al., 2003 Combined
Fisk, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
Jacobsen, et al., 2004 Combined
McCardle, et al., 2004 Combined
Montgomery, et al., 2005 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
Wareing, Fisk, et al., 2004 Combined
Yip & Lee, 2005 Combined
Zakzanis, et al., 2002 Combined
Fixed
Random
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
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Figure 23:  Aggregated estimated effect size using Hedge’s g and the random effects model with 
one study removed. 
 
Study name Outcome Hedges's g (95%  CI) with study removed
Back-Madruga, et al., 2003 Combined
Bhattachary & Powell, 2001 Combined
Bond, et al., 2004 processing speed
Croft, et al., 2001 Combined
Curran & Verheyden, 2003 Combined
Daumann, et al., 2003 Combined
Daumann, et al., 2004 LGT-3 Logos immediate recall
Fisk, et al., 2004 Combined
Fox, et al., 2002 Combined
Fox, Parrott, et al., 2001 Combined
Gouzoulis-Mayfrank, et al., 2000 Combined
Gouzoulis-Mayfrank, et al., 2003 Combined
Halpern, et al., 2004 Combined
Hanson & Luciana, 2004 Combined
Heffernan, et al., 2001 study 2 Combined
Jacobsen, et al., 2004 Combined
McCann, et al., 1999 Combined
McCardle, et al., 2004 Combined
Montgomery, et al., 2005 Combined
Morgan, 1998 study 1 Combined
Morgan, 1998 study 2, 1999 Combined
Parrott, et al., 1998 Combined
Reneman, et al., 2000 Rey Auditory Verbal Learning Test delayed recall
Reneman, Lavalaye, et al., 2001 Combined
Reneman, Majoie, et al., 2001 Combined
Rodgers, 2000 Combined
Simon & Mattick, 2002 Combined
Verkes, et al., 2001 Combined
von Geusau, et al., 2004 men Combined
von Geusau, et al., 2004 women Combined
Wareing, et al., 2000 Combined
Wareing, et al., 2005 Combined
Wareing, Fisk, et al., 2004 Combined
Wareing, Murphy, et al., 2004 Combined
Yip & Lee, 2005 Combined
Zakzanis, et al., 2002 Combined
Zakzanis, et al., 2003 Combined
-1.00 -0.50 0.00 0.50 1.00
Negative relationship Positive relationship
 
The last line of the Forrest plot represents the overall effect size estimate, computed under the random effects model. 
 
 
 
 103
